Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
Confidential and Proprietary Page 1 of 96Clinical Study Protocol: PT010018 -00
Study Title: A Study to Assess the Pharmacokinetics and Safety of PT010 in
Subjects With Moderate to Severe COPD Following Single and Repeat 
Dose Administration
Study Number: PT010018
Study Phase: I
Product Name: [CONTACT_6214]010: Budesonide, Glycopyrronium, and Formoterol Fumarate 
Inhalation Aerosol, Metered Dose Inhaler (BGF MDI)
Indication: Chronic Obstructive Pulmonary Disease
Investigators: Single Center
Sponsor: Pearl Therapeutics, Inc.
Sponsor Contact:
[CONTACT_345257]: 1.0 14 June 2017
Confidentiality Statement 
Property of Pearl Therapeutics
This document is confidential and may not be used, divulged, pu blished or otherwise 
disclosed without consent of Pearl Therapeutics Inc.
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
Confidential and Proprietary Page 2 of 96SYNOPSIS 
Sponsor:
Pearl Therapeutics, Inc.
Name [CONTACT_26323]:
PT010: Budesonide, Glycopyrronium , and Formoterol Fumarate Inha lation Aerosol, Metered 
Dose Inhaler (BGF MDI)
Name [CONTACT_19138]:
Budesonide, Glycopyrroniu m, and Formoterol Fumarate
Study Title:
A Study to Assess the Pharmacokinetics and Safety of PT010 in S ubjects With Moderate to 
Severe COPD Following Single and Repeat Dose Administration
Study Protocol Number: PT010018-00
Study Phase: I
Primary Objective:
•To assess the pharmaco kinetic (PK) profile of  BGF MDI in subject s with moderate 
to severe COPD after single dose administration on the f irst treatment day and after  7 
days of repeat dosing.
Safety Objective:
•To assess the safety and toler ability of BGF MDI in subjects wit h moderate to severe 
COPD after single dose adminis tration on the first  treatment da y and after 7 days of 
repeat dosing
Study Design:
This is a Phase I open-label, single center stu dy to assess the PK and safety of  BGF MDI 
320/14.4/9.[ADDRESS_428683] treatment day (Day 1) and will be 
assessed again after [ADDRESS_428684] a d ocumented history (ie, within 
the past 12 months) of COPD defined as a post- bronchodilator forced expi[INVESTIGATOR_3741] 1 
second (FEV 1)/forced vital capacity (FVC) <0.[ADDRESS_428685]-bronchodilator F EV 1<80% 
predicted normal. Subjects without historical documentation mus t meet these criteria at the 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428686] a pre-bronchod ilator FEV 1 between ≥50 and 
<80% predicted normal during S creening after withholding all COPD medications and after 
withholding the use of albuterol  for at least 6 hours prior to the assessment. All eligible 
subjects will receive Sponsor-provided Ventolin® hydrofluoroalkane (HFA; albuterol sulfate 
inhalation aerosol) for rescue use throughout the study. During  the Screening Period, eligible 
subjects will continue the use of t heir regular COPD maintenanc e therapy. However, any 
medication containing any one or more of the components of BGF (all formulations of 
budesonide, glycopyrronium  or formoterol fumarate) are prohibited a minimum of [ADDRESS_428687] dose for the day . Study subjects 
will use a Placebo MD I for training purposes only to demonstrate proper use of the M DI on 
Day -1, Day 1, Day 7, and Day 8. The Treatment Period of 8 days will start on Day 1. BGF 
MDI 320/14.4/9.6 μg will be adminis tered as oral inhalation as follows:  
• Single dose administration on the morning of Day 1 (Visit 3) fo llowed by [CONTACT_345258] 24 hours  
• Twice daily (BID) dosing every morning and evening on Days 2 th rough Day 7 
approximately 12 hours apart  
• Single dose administration on the morning of Day 8 (Visit 5) fo llowed by [CONTACT_345258] [ADDRESS_428688] PK 
blood draw and will continue to administer BGF MDI BID at home on Days 2 through 7. 
Subjects will return to the clinic for inpatien t admission on Day 7 (Visit 4) and administer the 
evening dose of study drug at the clinic.  
Subjects will undergo safety assessments and serial blood draws on Day [ADDRESS_428689] 
will be discharged from the clinic on the evening of Day 8.  
Subjects will return to appropriate COPD maintenance medication s after the final 
assessments on Day 8  are completed. 
Study Population: 
The planned study population will include approximately 30 male  and female adult subjects 
with moderate to severe COPD who will be enrolled to provide a pproximately 24 subjects 
who will complete the study. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428690] Name & Dose Product Strength Dosage Form/ 
Fill Count Administration 
BGF MDI 320/14.4/9.6 μg 
ex-actuator 160/7.2/4.8  μg/actuation MDI/ 
120 inhalations 2 inhalations BID 
 
Duration of Treatment:  
It is planned that each subject will receive study drug for 8 d ays. 
Duration of Study: 
The entire study period is scheduled to take approximately 7  weeks (expected range between 
2.5 to 7 weeks) for each individual subject. The study is antic ipated to run for approximately 
[ADDRESS_428691]- dose on Day 1 and Day 8. 
Primary PK Endpoints  
• Maximum plasma concentration (C max) 
• Area under the plasma concentration-time curve from 0 to 12 hou rs (AUC 0-12) 
• Area under the plasma concentration-time curve from [ADDRESS_428692] 
measureable plasma concentration (AUC 0-tlast) 
 
Secondary PK Endpoints  
• Time to maximum plasma concentration (t max) 
• Area under the plasma concentration-time curve from 0 extrapola ted to infinity 
(AUC 0-∞)  
Safety Endpoints: 
• Adverse events (AEs) 
• 12-lead electrocardiograms (ECGs) 
• Clinical laboratory testing  
• Vital sign measurements 
Statistical Methods: 
Safety Analyses : Descriptive statistics will be provided for ECG, vital signs, a nd laboratory 
measurements as appropriate. The  frequencies of AEs and the num ber and percentage of 
subjects with AEs will also be provided.  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
Confidential and Proprietary Page 5 of 96PK Analyses: The accumulation ratios for AUC 0-12and C maxand the linearity ratio 
AUC 0-12/AUC 0-∞between Day [ADDRESS_428693]. 
Descrip tive statistics without model ad justment will be used to descri be the other 
budesonide, glycopyrronium ,and formoterol PK parameters after treatment with BGF MDI. 
The time to steady state for each analyte will be estimated usi ng the effective rate of 
accum ulation.
Sample Size: This study is descriptive in nature. The planned sample size of  approximately 
30 enrolled subjects is selected to provide approximately 24 co mpleters for assessment of the 
single- and multiple-dose PK of BGF MDI in subjects with COPD.
Date of Protocol:
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428694] Identification ........................................ .....................................................27  
5.4 Prior, Concomitant, and Prohibited Medications ................ ...................................27  
5.4.1  Prior, Concomitant, and Prohibited COPD Medications ........... ..................27  
5.4.2  Other Prohibited Medications .................................. ....................................29  
5.5 Other Study Restrictions ...................................... ..................................................30  
5.5.1  Dietary Restrictions .......................................... ...........................................30  
5.5.2  Illicit Drugs and/or Drugs of Abuse Restriction ............... ...........................31  
5.6 Study Withdrawal .............................................. ....................................................31  
6 LABELING, PACKAGING, STORAGE, DISPENSING, AND RETURN OF 
CLINICAL SUPPLIES ............................................. .......................................................32  
6.1 Description of Study Drug ..................................... ................................................32  
6.2 Other Sponsor-Provided Medications Used in the Study .......... ............................32  
6.3 Packaging and Labeling ........................................ .................................................33  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 7 of 96 6.4 Storage Requirements .......................................... ..................................................34  
6.5 Instructions for Preparation of Study Drug for Administration . ............................34  
6.6 Study Drug Dosing ............................................. ...................................................35  
6.7 Emergency Unblinding of Treatment Assignment .................. ..............................36  
6.8 Study Drug Accountability/Return of Clinical Supplies ......... ..............................[ADDRESS_428695]-Bronchodilator Assessments ...................... ...........................38  
7.5 PK Assessments ................................................ .....................................................39  
7.5.1  Blood Sample Collection Schedule .............................. ...............................39  
7.5.2  Procedures for Shippi[INVESTIGATOR_345182] ............................... .................................39  
7.5.3  Storage and Destruction of PK Samples ......................... .............................39  
7.6 Safety Assessments ............................................ ....................................................40  
7.6.1  Medical History ............................................... ............................................40  
7.6.2  Physical Examination........................................... ........................................40  
7.6.3  Vital Signs ................................................... .................................................40  
7.6.4  12-Lead ECG ................................................... ............................................40  
7.6.5  Clinical Laboratory Tests ..................................... ........................................41  
[IP_ADDRESS]  Laboratory Sample Collection, Storage and Shippi[INVESTIGATOR_007] ............ ...........[ADDRESS_428696]........................................ .........................................44  
[IP_ADDRESS]  LABA and LAMA Effects ......................................... ........................44  
[IP_ADDRESS]  Local Steroid Effects.......................................... ................................44  
7.7.9  Clinical Laboratory AEs ....................................... .......................................45  
7.7.10  SAEs .......................................................... ..................................................45  
[IP_ADDRESS]  Reporting SAEs ................................................ .................................46  
[IP_ADDRESS]  Supplemental Investigations of SAEs ........................... .....................46  
[IP_ADDRESS]  Post-Study Follow-up of AEs ................................... .........................46  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 8 of 96 [IP_ADDRESS]  Notification of Post-Treatment SAEs ........................... .....................47  
[IP_ADDRESS]  IRB/IEC Notification of SAEs................................... ........................47  
[IP_ADDRESS]  Health Authority Safety Reports ............................... .........................47  
7.7.11  Overdose ...................................................... ................................................47  
7.7.12  Pregnancy ..................................................... ................................................47  
7.7.13  Paternal Exposure ............................................. ...........................................48  
7.8 Termination of the Study ...................................... .................................................48  
8 STUDY ACTIVITIES .............................................. .......................................................49  
8.1 Screening Visit 1 (Screening, Day -28 to Day -2) .............. ...................................55  
8.2 Visit 2 (Admission to Clinic, Day -1) ......................... ...........................................55  
8.3 Visit 3 (Day 1/Day 2 of the Treatment Period).................. ....................................[ADDRESS_428697] (Days 2 to 7 of the Treatment Period) ....... .............................57  
8.5 Visit 4 (Day 7) ............................................... ........................................................57  
8.6 Visit 5 (Day 8) ............................................... ........................................................[ADDRESS_428698]/Patient Records .................... ..............................63  
10.6  Quality Control and Assurance ................................. .............................................63  
10.7  Data Management ............................................... ...................................................63  
10.8  Study Monitoring .............................................. .....................................................63  
10.9  Retention of Data ............................................. ......................................................64  
10.10  Financial Disclosure........................................... ....................................................65  
10.11  Investigator’s Final Report  .............................................................. ......................65  
10.12  Publication Policy ............................................ ......................................................65  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428699] ................................................ .........................................................67  
12 APPENDICES .................................................... .............................................................68  
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428700] OF IN-TEXT TABLES 
Table 5-1  Prohibited Budesonide, Glycopyrronium, and Formoterol Fumarate 
COPD Medications .............................................. ........................................................28  
Table 5-2  Other Prohibited COPD Medications ............................. ........................28  
Table 5-3  Other Prohibited Medications .................................. ..............................29  
Table 6-1  Study Drug Description......................................... .................................32  
Table 6-2  Other Medications Provided by [CONTACT_2728] ......................... ......................33  
Table 7-1  Laboratory Tests .............................................. .......................................41  
Table 8-1  Schedule of Events for Screening, Treatment, and Follow-up .... ..........50  
Table 8-2  Timing of Assessments on Day 1 (Visit 3) ...................... ......................53  
Table 8-3  Timing of Assessments on Day 8 (Visit 5) ...................... ......................[ADDRESS_428701] ors for Time, Volume and Flow 
on Graphical Output ........................................... ..........................................................90  
Table A1-2  Summary of Equipment Quality Control .......................... .....................91  
Table A1-3  Range and Accuracy Recommendations Specified for Forced 
Expi[INVESTIGATOR_345183] .......................................... ........................................................93  
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428702] OF IN-TEXT FIGURES 
Figure 4-1.  Study Design .................................................. ........................................23  
Figure A1-1  Example of a Usable Spi[INVESTIGATOR_244916] ................................. ...........................87  
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428703] Instructions for Use of BGF MDI and Placebo MDI ....... .........70  
Appendix 3  Instructions for Use of Ventolin HFA Inhalation Aerosol Device ........79  
Appendix 4  Spi[INVESTIGATOR_280798] ................................ .............................87  
Appendix 5  Spi[INVESTIGATOR_345184] ........................ ..................89  
Appendix 6  Sponsor Signatory ............................................. .....................................95  
Appendix 7  Investigator’s Signature  .............................................................. ...........96  
 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428704] 
measureable plasma concentration 
AUC 0-∞ Area under the plasma concentrat ion-time curve from 0 extrapola ted to 
infinity 
BFF MDI Budesonide and Formoterol Fumarate Metered Dose Inhaler 
BGF MDI  Budesonide, Glycopyrronium, and F ormoterol Fumarate Metered Dos e 
Inhaler 
BID Twice daily 
BP Blood pressure 
CI Confidence interval 
CL/F Apparent total body clearance 
Cmax Maximum plasma concentration 
COPD Chronic obstructive pulmonary disease 
CV% Coefficient of variation 
CYP3A4 Cytochrome P450 3A4 
ECG Electrocardiogram 
eCRF Electronic case report form 
ERS European Respi[INVESTIGATOR_345185] 1 Forced expi[INVESTIGATOR_3741] 1 second 
FVC Forced vital capacity 
GCP Good Clinical Practice 
GOLD Global Initiative for Chronic Obstructive Lung Disease 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428705] 
PK Pharmacokinetics 
PT009 Budesonide and Formoterol Fumarate Inhalation Aerosol 
PT010  Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation 
Aerosol 
QTcF Fridericia-corrected QT interval 
RAC(C max) Accumulation ratio for C max 
RAC(AUC 0-12) Accumulation ratio for AUC 0-[ADDRESS_428706] 
SAP Statistical analysis plan 
t1/2 Apparent terminal elimination half-life 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 15 of 96 TEAE Treatment-emergent adverse event 
tmax Time to maximum plasma concentration 
US [LOCATION_002]  
Vd/F Apparent volume of distribution 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 16 of 96 TRADEMARK INFORMATION 
Trademarks not owned by [CONTACT_1034]: 
Foradil Seebri 
Perforomist Symbicort 
Pulmicort Turbuhaler 
Rhinocort Xolair 
Robinul  
 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 17 of 96 1 INTRODUCTION AND STUDY RATIONALE 
Chronic obstructive pulmonary di sease (COPD) is a common preven table and treatable 
disease characterized by [CONTACT_345259][INVESTIGATOR_345186]/or alveolar abnormalities usually caused by [CONTACT_345260], the most common of which is cigarette smoke . Exacerbations and 
co-morbidities contribute to the overall severity in individual  patients. Chronic obstructive 
pulmonary disease is a leading cause of morbidity and mortality  worldwide and results in a 
significant economic and socia l burden that is both substantial  and increasing. Pharmacologic 
therapy in COPD is used to reduce symptoms, reduce the frequenc y and severity of 
exacerbations, and improve health s tatus and exercise tolerance  (Global Initiative for Chronic 
Obstructive Lung Disease [GOLD 2017]). 
Bronchodilator medications are central to the symptomatic manag ement of COPD. The 
principal bronchodilator treatments are β2-agonists, anticholinergics, and methylxanthines 
used as monotherapy or in combi nation. Treatment with long-acti ng bronchodilators is more 
convenient and more effective at producing maintained symptom r elief than treatment with 
short-acting bronchodilators. 
Regular treatment with inhaled corticosteroids (ICS) improves s ymptoms, lung function, and 
quality of life and reduces the frequency of exacerbations in s ubjects with COPD with a 
forced expi[INVESTIGATOR_3741] 1 second (FEV 1) value of <60% of predicted. Withdrawal from 
treatment of ICS may lead to exacerbations in some patients. Wh en combined with a 
long- acting β2-agonist (LABA), an ICS is more effective than the individual c omponents in 
improving lung function and quality of life and reducing exacer bations in subjects with 
moderate to very severe COPD (GOLD 2017). 
Pearl Therapeutics, Inc. (here inafter referred to as Pearl) is developi[INVESTIGATOR_007] a fixed-dose 
ICS/long-acting muscarinic antagonist (LAMA)/LABA triple combin ation product, 
Budesonide, Glycopyrronium, a nd Formoterol Fumarate Inhalation Aerosol (PT010), 
hereafter referred to as Budesonide, Glycopyrronium, and Formot erol Fumarate Metered 
Dose Inhaler (BGF MDI), for the treatment of patients with COPD . Budesonide and 
Formoterol Fumarate Inhalation Aerosol (PT009), hereinafter ref erred to as Budesonide and 
Formoterol Fumarate (BFF) MDI is also being developed as a twic e daily (BID) fixed dose 
ICS/LABA treatment for patients with COPD. Glycopyrronium, and Formoterol Fumarate 
Inhalation Aerosol MDI is approve d in the [LOCATION_002] (US) as  a BID maintenance 
bronchodilator treatment in patien ts with COPD under the traden ame Bevespi [INVESTIGATOR_345187]®. 
Budesonide is a well-established  corticosteroid approved worldw ide in monotherapy and 
combination therapi[INVESTIGATOR_254155] t reatment of asthma and allergic rhinitis. It is available in both 
intranasal and orally inhaled for mulations. Inhaled budesonide in combination with 
formoterol fumarate dihy drate (ie, Symbicort® [[COMPANY_008], LP]) is approved for use in 
patients with asthma and COPD. 
Glycopyrronium is a LAMA that exerts its bronchodilatory effect  via muscarinic receptors 
located on smooth muscle cells within the trachea and bronchi. Glycopyrronium is approved 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 18 of 96 in many countries in multiple fo rmulations for different indica tions, including for the 
treatment of COPD. 
Formoterol fumarate is a selecti ve LABA approved worldwide for use in asthma and COPD. 
In addition, formoterol fumarate is also approved worldwide in combination with budesonide 
(eg, Symbicort MDI, Symbicort Turbuhaler® [[COMPANY_008], LP]) for use in patients with 
asthma and COPD. When inhaled, formo terol fumarate acts locally  in the lung as a 
bronchodilator. Formoterol fumarate stimulates β2-adrenoreceptors in the airways, inducing 
airway smooth muscle relaxation and reducing or preventing bron choconstriction. 
The purpose of this study is to determine the pharmacokinetics (PK) of BGF MDI in subjects 
with COPD following single and repeat administration. This will  allow determination of 
accumulation of each component of BGF MDI in plasma during stea dy-state administration. 
The plasma concentration data will also contribute to populatio n PK modeling. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 19 of 96 2 STUDY OBJECTIVES 
2.1 Primary Objective 
• To assess the PK profile of BGF M DI in subjects with moderate t o severe COPD 
after single dose administrati on on the first treatment day and  after 7 days of repeat 
dosing 
 
2.2 Safety Objective 
• To assess the safety and tolerability of BGF MDI in subjects wi th moderate to severe 
COPD after single dose adminis tration on the first  treatment da y and after 7 days of 
repeat dosing 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428707]-dose on Day 1 and Day 8. 
3.1.1 Primary PK Endpoints 
• Maximum plasma concentration (C max) 
• Area under the plasma concentration-time curve from 0 to 12 hou rs (AUC 0-12) 
• Area under the plasma concentration-time curve from [ADDRESS_428708] 
measureable plasma concentration (AUC 0-tlast) 
 
3.1.2 Secondary PK Endpoints 
• Time to maximum plasma concentration (t max) 
• Area under the plasma concentration-time curve from 0 extrapola ted to infinity 
(AUC 0-∞) 
 
3.1.3 Other PK Endpoints 
The following PK parameters will be calculated at Day 1 only: 
• Apparent terminal elimination half-life (t 1/2) 
• Apparent total body clearance (CL/F) 
• Apparent volume of distribution (Vd/F) 
• Terminal elimination rate constant ( λz) 
 
The following will be derived based on ratios of Day 8 values t o Day 1 values: 
• Accumulation ratio for C max (RAC [C max]) 
• Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) 
• Linearity ratio (Rlin [AUC 0-12/AUC 0-∞]) 
 
Other PK parameters may be calculated, as appropriate. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 21 of 96 3.2 Safety Endpoints 
• Adverse events (AEs) 
• 12-lead electrocardiograms (ECGs) 
• Clinical laboratory testing  
• Vital sign measurements 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 22 of 96 4 INVESTIGATIONAL PLAN 
4.1 Overall Study Design and Plan 
This is a Phase I open-label, s ingle center study to assess the  PK and safety of BGF MDI 
320/14.4/9.[ADDRESS_428709] tr eatment day (Day 1) and will be 
assessed again after [ADDRESS_428710] a d ocumented history (ie, within 
the past 12 months) of COPD define d as a post-bronchodilator FE V1/forced vital capacity 
(FVC) <0.[ADDRESS_428711]-bronchodilator FEV 1 <80% predicted normal. Subjects without 
historical documentation must meet  these criteria at the Screen ing Visit. In addition, subjects 
must have a pre-br onchodilator FEV 1 betwe en ≥50 and <80% predicted normal during 
Screening after withholding all COPD medications and after with holding the use of albuterol 
for at least 6 hours prior to the assessment. All eligible subj ects will receive Sponsor-
provided Ventolin® hydrofluoroalkane (HFA; albuterol sulfate inhalation aerosol) for rescue 
use throughout the study. During the Screening Period, eligible  subjects will continue the use 
of their regular COPD maintenance therapy. However, any medicat ion containing any one or 
more of the components of BGF (all formulations of budesonide, glycopyrronium, or 
formoterol fumarate) are prohibited a minimum of [ADDRESS_428712] dose  for the day. Study subjects 
will use a Placebo MDI for training purposes only to demonstrat e proper use of the MDI on 
Day -1, Day 1, Day 7, and Day 8. The Treatment Period of 8 days  will start on Day 1. BGF 
MDI 320/14.4/9.6 μg will be adminis tered as oral inhalation as follows: 
• Single dose administration on the morning of Day 1 (Visit 3) fo llowed by [CONTACT_345258] 24 hours 
• BID dosing every morning and evening on Days 2 through Day 7 ap proximately 12 
hours apart  
• Single dose administration on the morning of Day 8 (Visit 5) fo llowed by [CONTACT_345258] [ADDRESS_428713] PK 
blood draw and will continue to administer BGF MDI BID at home on Days 2 through 7. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428714] 40 and no older than 80 years of age at Visit 1 
3. Agree to one of the following to prevent pregnancy: 
- Non-childbearing potential (ie, physiologically incapable of be coming pregnant, 
including any female who is [ADDRESS_428715]-menopausal, or surgica lly sterile [defined as 
having a bilateral oophorectomy, hysterectomy or tubal ligation ]) 
Note:  For purposes of this protocol, menopausal women are defined as  women 
≥50 years old who are amenorrheic for 12 consecutive months or mor e following 
cessation of all exogenous hormonal treatment 
- Practice abstinence 
- If a sexually active woman of childbearing potential, agrees to  prevent pregnancy by 
[CONTACT_345261] (ICF) is signed until 2 weeks after the final dose  of study drug is taken: 
◦ Hormonal contraception (eg, oral contraceptive, contraceptive i mplant, or 
injectable hormonal contraceptive) 
◦ Double-barrier birth control (eg , condom plus intrauterine devi ce, diaphragm plus 
spermicide or condom plus spermicide) 
◦ Maintenance of a monogamous relationship with a male partner wh o has been 
surgically sterilized by [CONTACT_43406] 
- If a woman of childbearing potential, have a negative serum pre gnancy test at Visit [ADDRESS_428716] agree to use a double-barrie r method of 
contraception (condom with sper micide) from the first dose of s tudy drug until 
[ADDRESS_428717] not donate sperm during  their study 
participation period 
4. COPD Diagnosis: An established clinical history of COPD as defi ned by [CONTACT_345262] (ATS)/Europea n Respi[INVESTIGATOR_3764] (ERS) (Cell i 2004) characterized 
by [CONTACT_345263] i nflammatory response of 
the lungs to noxious particles or gases, primarily caused by [CONTACT_345264]. This 
includes demonstration (at the Screening Visit or within the pa st 12 months) of a post-
bronchodilator FEV 1/FVC ratio of <0.[ADDRESS_428718]-bronchodilator FEV 1 of <80% 
predicted normal value. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 25 of 96 5. Tobacco Use: Current or former s mokers with a history of at lea st 10 pack-years of 
cigarette smoking. Number of pack-years= (number of cigarettes per day/20) × number of 
years smoked (eg, 20 cigarettes per day for 10 years, or 10 cig arettes per day for 20 years 
represent 10 pack-years). 
6. COPD Severity: At Visit 1, pre-bronchodilator FEV 1/FVC ratio must be <0.[ADDRESS_428719] be ≥50% and <80% predicted normal value calcula ted 
using National Health and Nutrition Examination Survey (NHANES)  III reference 
equations.  
7. Screening clinical laboratory tests must be acceptable to the I nvestigator. 
8. Screening ECG must be acceptable to the Investigator. 
9. Compliance: Must be willing to remain at the study center as re quired per protocol to 
complete all visit assessments. 
10. Demonstrate correct MDI administration technique. Spacer use is  prohibited 
 
5.2 Exclusion Criteria 
Subjects who meet any of the following criteria will be exclude d from the study: 
1. Pregnancy and Lactation: Women who are pregnant or lactating, o r are planning to 
become pregnant during the course of the study, or women of chi ldbearing potential who 
are not using an acceptable method of contraception. 
2. Asthma: Subjects who have a diagnosis of asthma. ( Note:  Subjects with a primary 
diagnosis of COPD but a prior history of asthma that is remote (ie, more than 10 years 
since it has been an active diagnosis) are eligible. 
3. Alpha-1 Antitrypsin Deficiency: Alpha-1 antitrypsin deficiency as the cause of COPD. 
4. Other Respi[INVESTIGATOR_9501]: Includes other active pulmonary di sease such as active 
tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fi brosis, primary pulmonary 
hypertension, interstitial lung  disease and uncontrolled sleep apnea (ie, in the opi[INVESTIGATOR_15960], severity of the disorder would impact the con duct of the study). 
5. Lung Resection: Subjects who have undergone lung volume reducti on surgery at any 
time in the past. 
6. Exacerbation: Subjects who have had a moderate or severe COPD e xacerbation (ie, an 
exacerbation for which the subject was hospi[INVESTIGATOR_345188]) within 3 months of Screening (Visit 1). 
7. Lower respi[INVESTIGATOR_6014]: Subjects who have had lower  respi[INVESTIGATOR_345189] 3 months prior to S creening (Visit 1). 
8. Spi[INVESTIGATOR_345190]: Subjects who cannot perform acceptable spi[INVESTIGATOR_345191]/ERS criteria (Miller 2005). 
9. Other Diseases: Subjects who have c linically significant medica l conditions, including 
but not limited to cardiovascular, neurological, psychiatric, h epatic, gastrointestinal, renal 
(creatinine clearance ≤30 mL/minute), immunological, glaucoma, symptomatic prostatic 
hypertrophy (if treated and asymptomatic, the subject is eligib le for enrollment), 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 26 of 96 endocrine (including uncontrolle d diabetes or thyroid disease),  or hematological medical 
problems. 
10. Clinically significant abnormal ECG: Subjects who in the opi[INVESTIGATOR_3078] n of the Investigator 
have a clinically significant abnormal 12-lead ECG. A clinicall y significant abnormal 
ECG is defined as (but not lim ited to) any of the following: 
- Clinically significant conduction abnormalities (eg, complete l eft bundle branch 
block, Wolff-Parkinson-White syndrome) 
- Clinically significant arrhythmias (eg, atrial fibrillation, ve ntricular tachycardia) 
- Fridericia-corrected QT interval ( QTcF) ≥500 msec in subjects with QRS <120 msec 
and QTcF ≥530 msec in subjects with QRS ≥120 msec  
- Ventricular rate <45 bpm 
- Evidence of second-degree (Mobitz Type II) or third-degree atri oventricular block 
- Pathological Q waves of [ADDRESS_428720] abnormalities deemed to be clinically significant by [CONTACT_737]. 
Note: Subjects with non-specific ST-T wave abnormalities that a re not deemed 
clinically significant (per Investigator) are allowed. 
11. Uncontrolled Hypertension: Subjects who have clinically signifi cant uncontrolled 
hypertension. 
12. Liver Function: Abnormal liver function tests defined as aspart ate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phosphatase, or total bilirubin ≥1.5 
times upper limit of normal on repeat testing 
13. Cancer: Cancer that has not been in complete remission for at l east 5 years 
Note:  Subjects with squamous cell carcinoma and/or basal cell carcin oma of the skin or 
localized prostate cancer that i n the opi[INVESTIGATOR_345192], is clinically controlled, and where the subject ’s participation in the study 
would not represent a safety concern, are eligible. 
14. Drug Allergy: Subjects who have a history of hypersensitivity t o any corticosteroid, 
β2-agonist, muscarinic anticholinergic, or any component of the M DI. 
15. Anemia: Subjects with anemia that is considered clinically sign ificant by [CONTACT_737] 
16. History of blood donation within 90 days before Screening 
17. Surgery: Subjects with major surgical interventions within 4 we eks before Screening or 
minor surgical interventions within 2 weeks before Screening 
18. Substance Abuse: Subjects with a known or suspected history of alcohol or drug abuse 
within [ADDRESS_428721] X-ray at 
Screening will not be required. 
20. Medication Prior to Spi[INVESTIGATOR_038]: Subjects who are medically unab le to withhold their 
short-acting bronchodilators for  the 6-hour period required pri or to spi[INVESTIGATOR_345193], Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 27 of 96 21. Prohibited COPD Medications: Unable to abstain from protocol-de fined prohibited 
medications during Screening and Treatment Periods (Section 5.4) 
22. Oxygen: Requirement for oxyge n therapy for >12 hours/day 
23. Non-compliance: Unable to comply with study procedures 
24. Affiliations with Investigator Site: Study Investigators, Sub-I nvestigators, study 
coordinators, employees of a participating Investigator, or imm ediate family members of 
the aforementioned are excluded from participation in this stud y. 
25. Questionable Validity of Consent: Subjects with a history of ps ychiatric disease, 
intellectual deficiency, poor mot ivation, substance abuse (incl uding drug and alcohol), or 
other conditions that might limit the validity of informed cons ent to participate in the 
study. 
26. Investigational Drugs or Devices: Treatment with an investigati onal study drug or 
participation in another clinical trial or study within the las t [ADDRESS_428722] 
identification number at Screening. Only subjects continuing to  meet entry 
inclusion/exclusion criteria  on Day [ADDRESS_428723] within 30 days prior 
to Visit 1 will be recorded on the P rior/Concomitant Medication s electronic case report form 
(eCRF). 
All concomitant medications taken during the study will be reco rded on the Concomitant 
Medications eCRF page with indication, total daily dose, and da tes of drug administration. 
Any additions, deletions, or chang es in the dose of these medic ations while in the study 
should be recorded on the eCRF. Any current ongoing medications , including over-the-
counter drugs and herbal supplement s, will be allowed provided they are not prohibited by 
[CONTACT_760] (see Section 5.4) and are approved by [CONTACT_737]. 
5.4.1 Prior, Concomitant, and Prohibited COPD Medications 
All formulations of budesonide, glycopyrronium, or formoterol f umarate used as 
monotherapy or in combination to treat COPD or any other condit ion (eg, allergic rhinitis) 
are prohibited for a minimum of 4 weeks before Visit 1 and duri ng the study. Examples of 
these medications are summarized in Table 5-1 . 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428724] Example Trade Names 
Budesonide-containing products Symbicort, Rhinocort®, Pulmicort® 
Glycopyrronium-containing products  Seebri®, Robinul®, Bevespi 
[INVESTIGATOR_345194]-containing products Symbicort, Foradil®, Perforomist®, Bevespi 
 
[INVESTIGATOR_345195] d have been maintained on a stabl e dose of this treatment 
for at least [ADDRESS_428725] dose for the day on Day -1 (Visit 2) and throu ghout the study.  
Additionally, short acting bronchodilators (eg, short- acting β2-agonists [SABAs] or short-
acting muscarinic antagonists [SAMAs] or their combinations) wi ll be withheld 6 hours prior 
to spi[INVESTIGATOR_345196]-
provided Ventolin HFA for use as needed for symptom relief. Add itional prohibited COPD 
medications and associated cessation periods prior to Visit 1 a re summarized in Table 5-2 . 
Table 5-2  Other Prohibited COPD Medications 
Prohibited COPD Medications Minimum Cessation Period Prior to 
Visit 1 
Parenteral, depot, and oral steroids 3 months 
Nebulized albuterol a nd/or ipratropi[INVESTIGATOR_345197] 6 hours 
Oral β-agonists 2 days 
Theophylline (total daily dose >400 mg/day)a 7 days 
SAMA 6 hours 
SABAb 6 hours 
Fixed-dose combinations of SAMA/SABA 6 hours 
Note: Subjects requiring chronic maintenance therapy with oral corticosteroids are excluded from participation 
in this study.  
Note: Subjects requiring maintenance therapy with roflumilast (or any  phosphodiesterase 4 inhibitor) are 
excluded from participation in this stud y. 
a Theophylline ≤400 mg/day is permitted provided the subject has been on a stable dose of therapy for at 
least 4 weeks prior to Visit 1. 
b Discontinue and use Sponso r-provided Ventolin HFA 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428726] not received these medi cations for a minimum of 
4 weeks before Visit 1. These medications are prohibited throug hout the course of the study.  
Table 5-3  Other Prohibited Medications 
Any drug with potential to significantly prolong the QT interva l (eg, quinidine, bepridil, sotalol, 
amiodarone, chlorpromazine, erythromycin, etc)a 
Non-selective beta-adrenergic antagonists 
Cardiac antiarrhythmics Class Ia, III 
Any drug that causes significant tachycardia (pseudoephedrine, appetite suppressants, etc) 
Other investigational drugsb 
CYP3A4 inhibitors, including amiodarone, diltiazem, cimetidine,  erythromycin, itraconazole, 
norfloxacin, ciprofloxacin, fluconazole, ketoconazole, clarithr omycin, fluvoxamine, mifepristone, 
nefazodone, and troleandomycin  
CYP3A4 inducers including barb iturates (eg, phenobarbital), car bamazepi[INVESTIGATOR_050], phenytoin, and rifampin 
Anticonvulsants (barbiturates, hydantoins, and carbamazepi[INVESTIGATOR_050]) f or the treatment of seizure disorderc 
Tricyclic antidepressantsd 
Antipsychotic drugs (phenothiazines)d 
Monoamine oxidase inhibitors 
Anti- tumor necrosis factor α antibodies (eg, infliximab and any other members of this class of drugs) 
Monoclonal antibodiese 
Systemic calcineurin inhibitors 
Protease inhibitors 
Systemic anticholinergicsf 
Chinese complementary and alternative bronchodilatory medicines , ie, herbal therapi[INVESTIGATOR_014] (eg, 
Astragalus membranaceus  [huáng qí], Panax ginseng  [ginseng products], Cordyceps sinensis , and  
A. membranaceus  [ghost moth caterpi[INVESTIGATOR_345198]]) 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 30 of 96 Table 5-3  Other Prohibited Medications 
Abbreviation: CYP3A4=cytochrome P450 3A4. 
Note: Benzodiazepi[INVESTIGATOR_345199].  
a Subjects who are on medications that have the potential to prol ong the QTc interval may be enrolled 
provided the dose has remained stable for at least [ADDRESS_428727] to participate in the study. Initiation of medications with the 
potential to significantly prolong the QT interval is prohibite d throughout the study. 
b Investigational therapi[INVESTIGATOR_328401] 30 days or 5  half-lives (whichever is longer) prior to 
Screening. 
c Anticonvulsants for conditions other than seizures may be start ed and stopped at any time prior to the study 
and throughout the Treatment Period. 
d Antipsychotic agents and tricyclic antidepressants used for pre viously diagnosed underlying medical 
conditions are allowed if, in the opi[INVESTIGATOR_689], there are no concerns regarding subject safety, 
and if the subject has been on  a stable dose for at least 6 wee ks. 
e Investigators should consult t he Medical Monitor to determine the appropriateness and safety of continuing 
study drug on a case by [CONTACT_413] (eg, XOLAIR® [omalizumab] will not be allowed, whereas a monoclonal 
for another indication such as osteoporosis may be allowed afte r consultation). 
f If systemic anticholinergics are used for treatment of overacti ve bladder and the treatment has been 
constant for at least [ADDRESS_428728]’s safety and well -being 
may be given at the Investigator’s discretion. 
5.5 Other Study Restrictions 
5.5.1 Dietary Restrictions 
Fasting (at least 6 hours) is required for clinical laboratory testing at Visit 1, Visit 2 (Day -1), 
and Visit 5 (Day 8). 
Fasting (at least 6 hours) is required prior to administration of BGF MDI on serial PK sample 
collection days (Days 1 and 8). Food may be consumed [ADDRESS_428729] xanthine (caffeine)-containing foods, beverages, or medications for 
at least [ADDRESS_428730] dose on the days of 
serial PK assessments (Day1 and Day 8). Examples of such produc ts include coffee, tea, 
chocolate, and cola. Decaffein ated beverages are acceptable. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 31 of 96 5.5.2 Illicit Drugs and/or Drugs of Abuse Restriction 
Illicit drugs and/or drugs of abuse will not be allowed from wi thin [ADDRESS_428731] at the occurrence of 
any or all of the following: 
• Protocol deviation 
• AE 
• COPD exacerbation 
• Subject becomes pregnant 
• Clinically significant change in a laboratory parameter(s) 
• Termination of the study by [CONTACT_343884] 
• Request by [CONTACT_345265] 
• Investigator’s disc retion 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 32 of 96 6 LABELING, PACKAGING, STORAGE, DISPENSING, AND 
RETURN OF CLINICAL SUPPLIES 
Study drug will be packaged to support enrollment of the study in an open-label fashion for 
the 8-day Treatment Period. Clin ical supplies will be packaged according to a component 
schedule generated by [CONTACT_345266]. 
6.1 Description of Study Drug 
In this protocol, “study drug” refers to an active ingredient or placebo being tested or used as a reference in the study (International Conference on Harmonisa tion [ICH] E6 R1). The 
study drug used in this study is described in Table 6-1 . Instructions for use/priming are 
provided in Appendix 2 . Subjects meeting all study eligibility criteria (Section 5) will be 
assigned to open-label study dru g at Visit [ADDRESS_428732] Name & Dose  Product Strength  Dosage 
Form/Fill Count  Administration  
BGF MDI 320/14.4/9.6
 μg 
ex-actuator 160/7.2/4.8  μg/actuation MDI/120 
inhalations 2 inhalations BID 
Note: Study drug will be administered by [CONTACT_345267]. A sin gle dose of study drug will be administered on 
Day 1 , and BID doses will be administered Day 2 through Day 7, with a final single administration of study 
drug occurring on the morning of Day 8. Administration of study  drug should occur at approximately the same 
time of day approximately 12 hours apart.  
 
6.2 Other Sponsor-Provided Medications Used in the Study 
Other Sponsor-provided medications used during the study are de scribed in Table 6-2 . The 
manufacturer’s instructions for administrati on, cleaning, and storage are provided in 
Appendix 2  and Appendix 3 . 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428733] Name & 
Dose Product Strength Dosage Form/Fill 
Count Administration 
Albuterol sulfate  
inhalation aerosol 90
 μg 
ex-actuator Ventolin HFA 
Each inhalation 
contains 108 μg 
albuterol sulfate 
corresponding to 
90 μg albuterol base 
from the mouthpi[INVESTIGATOR_345200]/[ADDRESS_428734]-
bronchodilator 
testing at Visit 1 
Placebo MDIa Formulation does not 
contain active 
ingredient MDI 
120 inhalations Subjects will use the 
Placebo MDI for 
training purpose only 
to demonstrate 
proper use of the 
MDI on Day - 1, 
Day 1, Day 7, and 
Day 8 
a All Placebos MDIs are identical in  appearance to study drug; th ey have no active moieties and have a 
different labels because they are only used for training. 
 
6.3 Packaging and Labeling  
All clinical trial supplies will  be packaged by [CONTACT_1034]. 
Study drug (BGF MDI) will be packaged in a box and labeled with  a single label. Inside the 
box will be a labeled foil pouch containing a labeled MDI canis ter and actuator. 
Each box will be labeled with a 2-part label printed with black  ink and may include the 
following items: 
Lot # (Packaging Lot Trace ID) 
Space for entr y of screening # 
Component ID #  
Space for entry of randomization #  
Fill Count & Dosage Form  
Visit # (Space for Entry of Interval ID)  Storage Conditions 
Protocol #  
Country regulatory requirements  
Sponsor address  
Translation Key   
Abbreviations: #=number; ID=identification. 
 
Ventolin HFA will be provided as individually labeled MDIs with  a single label on the 
actuator and canister. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 34 of 96 Labels will be printed with black ink and may include the follo wing text: 
Lot # (Packaging Lot Trace ID) 
Space for entry of scr eening # 
Component ID #  
Space for entry of randomization #  
Fill Count & Dosage Form  
Visit # (Space for Entry of Interval ID)  Storage Conditions 
Protocol #  
Country regulatory requirements  
Sponsor address  
Translation Key   
 
Placebo MDI will be packaged in individual boxes and labeled fo r training purpose only. 
Inside the box will be a labeled foil pouch containing a labele d MDI canister and actuator 
6.4 Storage Requirements 
All study supplies should be kept in a locked cabinet or room w ith limited access. The 
temperature of the site’s storage area for study supplies must be monitored by [CONTACT_345268]. Documentation of 
temperature monitoring should be maintained at the site and ava ilable for review. All study 
supplies contain contents under pressure. Do not use or store n ear heat or open flame. 
Exposure to temperatures above 49° C (120°F) may cause bursting.  Never throw canisters 
into a fire or incinerator. Avoid spraying in eyes. 
BGF MDI and Placebo MDI should be stored below 25°C (77°F) in a  dry place. Excursions 
permitted up to 30°C (86°F).  
Ventolin HFA should be stored between 15°C and 25°C (59°F and 7 7°F). Store the inhaler 
with the mouthpi[INVESTIGATOR_280821]. For be st results, the inhaler should be at room temperature before 
use. 
6.[ADDRESS_428735] number and treatment visi t number on each of the 2-part  labels. 
All subjects will receive BGF MDI (320/14.4/9.6 μg). Site staff  will instruct study subjects 
on the proper use of an MDI using a bulk-supplied MDI (placebo) . Subjects must 
demonstrate correct use of the  MDI at Screening, Day -1, and be fore study drug dosing on 
Day 1, Day 7, and Day 8. 
All MDIs must be primed before the first use. Priming involves releasing [ADDRESS_428736] tre atment area. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428737] dose (2 puffs) 
of study drug should be taken by [CONTACT_345269] r site personnel supervision.  
The date and time of the sec ond puff should be recorded as the time of dose administration in 
the source and eCRF. 
Refer to Appendix 2  for additional instructions on the  administration and cleaning  of the 
BGF MDI and Placebo MDI. 
On serial PK days (Day 1 and Day 8), administration of BGF MDI will take place in a room 
separate from the room where blood samples will be drawn. Subje cts and clinic personnel 
will wear protective clothing and vinyl gloves which will be di scarded immediately after 
administration in the room us ed for inhalation, to avoid subseq uent contamination of blood 
samples, according to the routines at the clinic. The subjects will also wash their hands and 
faces with water and rinse and clean their mouths twice with 25  mL water (rinse and spit out) 
after the administration of BGF MDI. Each dose will consist of [ADDRESS_428738] should be instructed 
that subsequent morning study drug dosing should occur BID (2 p uffs in the morning and 2 
puffs in the evening) at approximately the same time every day,  and that evening dosing 
should occur as close as possib le to [ADDRESS_428739], treatment will comprise of single dose admini stration (Day 1), BID dosing 
(Day 2 through Day 7), and a single morning dose on Day 8. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 36 of 96 6.7 Emergency Unblinding of Treatment Assignment  
Not applicable - this is an open-label study.  
6.8 Study Drug Accountability/Return of Clinical Supplies 
Under no circumstances will the Investigator allow the study dr ug to be used other than as 
directed by [CONTACT_3181]. 
Investigational clinical supplies must be received by a designa ted person at the study site, 
handled and stored safely and pr operly, and kept in a secure lo cation to which only the 
Investigator and designated study personnel have access. Storag e conditions for the clinical 
supplies should be observed, moni tored and documented. Clinical  supplies are to be 
dispensed only in accordance with the protocol. 
The Investigator or designee is responsible for keepi[INVESTIGATOR_191179] e records of the clinical 
supplies received from the Sponsor, the amount dispensed to and  returned by [CONTACT_423], and 
the amount remaining at the conclusion of the study. Study drug  should be handled in 
accordance with instructions provided in this section. The Clin ical Monitor should be 
contact[CONTACT_345270] s where special or protective 
handling is indicated. At the end of the study, all clinical su pplies including partial and empty 
containers must be returned as directed by [CONTACT_1034]. 
Sites should check with the Pearl representative for appropriat e documentation that needs to 
be completed for drug accountability. 
The Investigator or designee should not open the individual cli nical supply containers until 
all pre-dose assessments have be en completed and the subject is  eligible to be enrolled in the 
study. Any deviation from this must be discussed with the with the Sponsor’s Medical Monitor or designee. 
For each subject, all used study drug materials will be collect ed. Used subject supplies will 
be kept at room temperature in a  secure and locked cabinet unti l returned to the Sponsor or 
designee. 
Note:  Used study drug will be stored separately from unused study dr ug. 
All product complaints (including device malfunctions) must be reported to the Sponsor or 
the Sponsor’s representative using the Produc t Complaints Form provided in each site’s 
regulatory binder. The Sponsor or the Sponsor’s representa tive will contact [CONTACT_345271], related testing and deter mine if further action is needed. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428740] (IRB)/Indepe ndent Ethics Committee 
(IEC) that is reviewing the study documents. The ICF will be ob tained for all subjects 
participating in the study. Subjects may withdraw consent at an y time. Participation in the 
study may be terminated at any time without the subject’s consent as determined by [CONTACT_3786]. 
7.[ADDRESS_428741] their at-home study 
drug dosing (refer to dose indicator instructions in Appendix 1 ). 
The subject is to return the compl eted diary at Day 7 (Visit 4) . The study coordinator will be 
responsible for reviewing the diary for completeness and accura cy with the subject before 
dosing study drug in the clinic . All fields should be completed  by [CONTACT_423]. The subject 
will sign (initial) and date each page of the diary on the day it was completed, and the study 
coordinator will initial and date ea ch diary page at the site v isit when the diary is returned to 
validate the authenticity of the entries. If discrepancies or o missions of data are observed at 
this review, the subject, not the study coordinator, should mak e the corrections. The subject 
should draw a single line through the error and initial and dat e all corrections. The subject 
should make all entries in the diary in blue or black ink. 
7.4 Pulmonary Function Tests 
Forced expi[INVESTIGATOR_345201] 1 and FVC will be assessed using the 
site's spi[INVESTIGATOR_345202], which must comply with the ATS/ERS  Task Forces 
recommendation for standardizati on of lung function testing (Mi ller 2005). All spi[INVESTIGATOR_345203], including FEV 1 and FVC maneuvers, will be perf ormed according to the ATS/ERS 
criteria (Miller 2005) ( Appendix 4 ). 
The volume accuracy of the spi[INVESTIGATOR_345204] a 3 L syringe across 3 
flow ranges (ie, low, medium, and high flows), with temperature  and barometric pressure 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428742] meet ATS/ERS specifica tions and must not be used 
beyond the expi[INVESTIGATOR_5695]. Requi red accuracy is ±3% (ie, 3.09 L to  2.91 L) (ATS/ERS). The 
results will be printed and maintained in a calibration log, wh ich will be monitored for 
compliance during the monitoring visits ( Appendix 5 ). 
Spi[INVESTIGATOR_345205] 1. 
7.4.[ADDRESS_428743] a confirmed diagnosis of 
COPD (defined as a post-bronchodilator FEV 1 <80% of predicted normal [calculated using 
NHANES III reference equations ] and a post-bronchodilator FEV 1/FVC ratio of <0.70). 
Documentation of the COPD diagnosis (defined as FEV 1 <80% predicted and FEV 1/FVC 
<0.70) within the past [ADDRESS_428744] a pre-bronchodi lator FEV 1 at Visit 1 that is 
≥50% and <80% of predicted normal  and a pre-bronchodilator FEV 1/FVC ratio of <0.70.  
7.4.[ADDRESS_428745] documentation of a pos t-bronchodilator FEV 1 <80% predicted and an 
FEV 1/FVC <0.[ADDRESS_428746] 12 months: 
• Perform pre-bronchodilator pulmonary function tests (PFTs) (wit hin 60 minutes) 
prior to administration of Ventolin HFA (all subjects) 
• Administer 4 puffs of Ventolin HFA (only subjects without docum entation in the 
past 12 months) 
• Perform post-bronchodilator PFTs  30 minutes after the administr ation of Ventolin 
HFA (only subjects without docum entation in the past 12 months)  
 To determine study eligibility criteria for a study subject, th e Investigator and/or designee 
will review the following: 
• Pre- and post-bronchodilator PFTs to ensure the maneuvers meet repeatability and 
acceptability criteria per ATS/ERS guidelines 
• Diagnosis of COPD is confirme d using historical or Visit [ADDRESS_428747] -bronchodilator 
assessments 
• Pre-bronchodilator FEV 1 is ≥50% and <80% predicted  and pre-bronchodilator 
FEV 1/FVC ratio is <0.70 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428748] 6 hours prior to dosing on se rial PK 
days (Day 1 and Day 8). Meals on Days [ADDRESS_428749]-dose blood samples are obtained. 
•Pre-dose sample collection - Days 1 (morning dose), 7 (evening dose), and 8 
(morning dose) ( Table 8-2  and Table 8-3 ) 
•Post-dose sample collection 
- Day 1 ONLY ( Table 8-2 ) 
- Day 8 ONLY ( Table 8-3 ) 
•The recommended time windows for post-dose PK assessments are a s follows: 
Time points Time windows
2 and 6 min  ±1 min  
20 and 40 min and 1 h  ±2 min  
2 and 4 h  ±5 min  
8, 10, 12, 18, and 24 h  ±10 min  
Collection and storage of PK samp les will be detailed in the la boratory manual. 
7.5.2 Procedures for Shippi[INVESTIGATOR_345206] n by [CONTACT_345272]. Instructions for sample handling, storage, and shippi [INVESTIGATOR_345207]. 
7.5.3 Storage and Destruction of PK Samples 
Samples for determina tion of study drug concentration in plasma  will be analyzed by 
 [CONTACT_345273]. Full details of the 
analytical method used will be de scribed in a separate bioanaly tical report. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 40 of 96 Pharmacokinetic samples will be  disposed of after the bioanalyt ical report finalization or 
6 months after issuance of the draft bioanalytical report (whic hever is earlier), unless 
requested for future analyses.  
Pharmacokinetic samples may be  disposed of or destroyed and ano nymized by [CONTACT_76435]. 
Additional analyses may be conducted on the anonymized, pooled PK samples to further 
evaluate and validate the analyt ical method. Any results from s uch analyses may be reported 
separately from the clinical study report. 
Incurred sample reproducibility a nalysis, if any, will be perfo rmed alongside the bioanalysis 
of the test samples. The res ults from the evaluation will not b e reported in the clinical study 
report but separately in a bioanalytical report. 
7.[ADDRESS_428750]’s family health history, history of hospi[INVESTIGATOR_059], and history of surgeries.  
7.6.2 Physical Examination 
A complete physical examination including evaluation of the fol lowing will be performed at 
Screening and on Day -1 and Day 8: 
• General appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), 
lymph nodes, respi[INVESTIGATOR_696], cardiova scular, musculoskeletal, abdo minal, extremities, 
neurological and dermatological. 
• Weight and height, assessed in ordinary indoor clothing with sh oes removed, will 
also be recorded during Screening only 
 
7.6.3 Vital Signs 
Vital signs including blood press ure (BP) and heart rate will b e assessed after the subject has 
been supi[INVESTIGATOR_2525] 5 minutes at the Screening Visit, Day -1, Day 7 , and Day 8 ( Table 8-1  and 
Table 8-3 ). 
7.6.4 12-Lead ECG 
Twelve-lead ECGs will be recorded at Screening, Day -1, and Day  8 (Table 8-1  and 
Table 8-3 ).  
Subjects should be supi[INVESTIGATOR_345208] 5 minutes be fore and during the ECG 
recording procedure. Subjects with any ECG abnormality should b e evaluated by [CONTACT_345274]. All clinically significant 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428751] dose of study drug throughout the  Treatment Period until the 
follow-up telephone will be reported a s treatment-emergent adve rse events (TEAEs) and 
followed closely by [CONTACT_345275]. 
7.6.[ADDRESS_428752] for at leas t 6 hours prior to any scheduled complete clinical laboratory 
assessment blood draw (chemistry and hematology). 
Laboratory testing (hematology with differential, chemistry, an d urinalysis) will be 
performed using standard methods. Blood and urine samples for t he clinical laboratory tests 
listed in Table 7-1  will be collected at Screening, Day -1, and Day 8. 
Standardized meals will be a dministered on Days 1, 2, and 8 at specified times after 
observing fasting times for blood draws. There are no restricti ons regarding clear fluid 
intake. 
Table 7-1 Laboratory Tests 
Hematology  Chemistry  
Hematocrita 
Hemoglobin  
Serum iron 
Ferritin  
Platelet count  
Red blood cell count 
White blood cell count 
White blood cell  differential 
Mean corpuscular volume  
Mean cell hemoglo bin 
Mean corpuscular hemoglobin concentration
 Creatinineb 
Potassium  
Sodium  
Chloride  
Magnesium  
Calcium  
Inorganic phosphate 
Glucose  
Urea  
Bilirubin ( total) 
Blood urea nitrogen  Bilirubin (direct) 
ALT  
AST  
Gamma -glutamyltransferase 
Alkaline phosphatase  
Total p rotein 
Albumin  
Urinalysis:  Macroscopic examination routinely including specific gravity, pH, protein, 
glucose, ketones, blood, and urobilinogen. A microscopic examin ation will be performed 
based on macroscopic results. 
Urine drug screen: A urine sample will be coll ected and analyzed (positive or nega tive) at 
Screening and  on inpatient admission days for drugs of abuse including amphetamine, opi[INVESTIGATOR_2573], 
cocaine, barbiturates, benzodiazepi[INVESTIGATOR_1651], and marijuana (tetrahyd rocannabinol).  
Alcohol breathalyzer test: A breathalyzer test will be performed at Screening and on 
inpatient admission days for the presence of alcohol (positive or negative).  
For all females: A serum hCG test at Screening and urine hCG test on inpatient a dmission 
days.  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 42 of 96 Table 7-1 Laboratory Tests 
Hematology  Chemistry  
Abbreviations: hCG=human chorionic gonadotropin. 
a Packed cell volume 
b Estimated glomerular filtration rate will be calculated by [CONTACT_345276][INVESTIGATOR_345209] 
 
[IP_ADDRESS] Laboratory Sample Collection, Storage and Shippi[INVESTIGATOR_345210], process ing, and shippi[INVESTIGATOR_345211]. 
Approximately [ADDRESS_428753]’s eCRF and on the AE Reporting Form. If the AE is 
unexpected, the Investigator shoul d report the AE immediately t o the Sponsor. In addition, 
certain AEs (as described in Section 7.7.10 ) are classified as ‘serious’ and must be reported 
no later than 24 hours after the Investigator recognizes/classi fies the event as a serious 
adverse event (SAE) to the Sponsor or its designee. 
In the case of SAEs, after discussing the details of the event,  the Investigator and the Medical 
Monitor may discontinue the subject from study drug. 
7.7.2 AE Definitions 
The following definitions of terms are guided by [CONTACT_11580], the U S Code of Federal 
Regulations (21 Code of Federal Regulations 312.32) and Europea n Union Directive 
2001/83/EC and are included herein. 
An AE is any untoward medical occurrence associated with the us e of a drug in humans, 
whether or not considered drug re lated. An AE (also referred to  as an adverse experience) 
can be any unfavorable and unintended sign (eg, an abnormal lab oratory finding), symptom, 
or disease temporally associated with the use of a drug, withou t any judgment about 
causality. An AE can arise from  any use of the drug (eg, off-la bel use, use in combination 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 43 of 96 with another drug) and from any route of administration, formul ation, or dose, including an 
overdose. 
Adverse events include, but are not limited to: 
• Any symptom or condition not previously reported by [CONTACT_423]  (medical history) 
• An exacerbation of a pre-existing symptom or condition 
• A significant increase in frequency or intensity of a pre-exist ing epi[INVESTIGATOR_89274] 
• A drug interaction 
• A condition first detected or diagnosed after study drug admini stration even though it 
may have been present prior to the start of the study  
 An AE does not include the following: 
• Medical or surgical procedures ( eg, surgery, endoscopy, tooth e xtraction, blood 
transfusion); the condition that leads to the procedure is an A E (eg, bleeding 
esophageal varices, dental caries) 
• Overdose of either study drug or concurrent medication without any clinical signs or 
symptoms 
• Abnormal laboratory values that are not clinically significant;  if accompanied by 
[CONTACT_23804]/symptoms, the signs or symptoms are considered an AE 
 
For subjects discontinuing study drug and withdrawing from the study, all AEs/SAEs will be 
collected through the 5- to 7-day follow up telephone call. 
7.7.[ADDRESS_428754] ing to the following 
guidelines: 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 44 of 96 Mild: Associated with no limitat ion of usual activities or only  slight discomfort; generally 
not requiring alteration or cessation of study drug administrat ion; and/or not needing 
therapeutic intervention. 
Moderate: Associated with limitation of usual activities or sig nificant discomfort; generally 
requiring alteration or cess ation of study drug administration;  and/or requiring therapeutic 
intervention. 
Severe: Associated with inability of subject to carry out usual  activities or very marked 
discomfort; considered to be lif e-threatening; resulting in sig nificant disability or incapacity; 
and requiring therapeutic intervention. 
7.7.[ADDRESS_428755] and each AE, 
and answer yes/no to the questi on. ‘Do you consider that there is a reasonable possibility that 
the event may have been caused by [CONTACT_7198]?’  
For SAEs, causal relationship will also be assessed for other m edication and study 
procedures. Note that for SAEs that could be associated with an y study procedure the causal 
relationship is implied as ‘yes’.  
7.7.[ADDRESS_428756] (AESIs) due to the 
class of drugs being studied. The se AEs will be captured throug h spontaneous reports and the 
reporting of these AESIs will be  described in the statistical a nalysis plan (SAP). Some events 
are described below but this is  not a comprehensive list of all  AESIs. 
[IP_ADDRESS] LABA and LAMA Effects 
Known effects of LAMAs and LABAs include cardiovascular effects , ocular disorders, 
urinary retention, gastrointestinal disorders, and anticholiner gic effects for LAMAs and 
cardiovascular, potassium, glucose  and tremor effects for LABAs . 
[IP_ADDRESS] Local Steroid Effects 
Local steroid effects include or al candidiasis, hoarseness, dys phonia, and throat irritation. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 45 of 96 7.7.9 Clinical Laboratory AEs 
Many laboratory abnormalities  observed during the course of a s tudy will be included under 
a reported AE describing a clinical syndrome (eg, elevated bloo d urea nitrogen and creatinine 
in the setting of an AE of renal failure, or decreased hemoglob in in a case of bleeding 
esophageal varices). In such cases, the laboratory abnormality itself (eg, elevated creatinine 
in a setting of renal failure) does not need to be recorded as an AE. However, isolated 
laboratory abnormalities should be  reported as AEs if they are considered to be clinically 
significant by [CONTACT_737]. 
Criteria for a "clinically significant" laboratory abnormality are the following: 
• A laboratory abnormality that leads to a dose-limiting toxicity  (eg, an abnormality 
that results in study drug dose reduction, suspension, or disco ntinuation) 
• A laboratory abnormality that resu lts in any therapeutic interv ention (eg, 
concomitant medic ation or therapy) 
• Other laboratory abnormality judg ed by [CONTACT_63033] o f any particular 
clinical concern (eg, significant fall in hemoglobin not requir ing transfusion) 
 For laboratory abnormalities that do not meet the above criteri a but are outside of normal 
range (eg, < or > normal reference range), the Investigator sho uld indicate whether the value 
is clinically significant or not clinically significant for the  subject. 
7.7.10 SAEs 
An AE is considered “serious” if, in  the view of the Investigator or Sponsor, it results in any 
of the following outcomes: 
• Death 
• A life-threatening AE 
• In patient hospi[INVESTIGATOR_345212]  
• A persistent or significant in capacity or substantial disruptio n of the ability to 
conduct normal life functions 
• A congenital anomaly/birth defect. 
 
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon appr opriate judgment, they may 
jeopardize the subject or subject and may require medical or su rgical intervention to prevent 
one of the outcomes listed in the  definition. Examples of such medical events include allergic 
bronchospasm requiring intensive t reatment in an emergency room  or at home, blood 
dyscrasias or convulsions that do not result in subject hospi[INVESTIGATOR_1916], or the development of 
drug dependency or drug abuse. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 46 of 96 Hospi[INVESTIGATOR_272] a pre-existing condition, including electiv e procedures, which has not 
worsened, does not constitute an SAE. 
An AE or suspected adverse reaction is consider ed “life threatening’ if, in the view of the 
Investigator or Sponsor, its occurrence places the subject at i mmediate risk of death. It does 
not include an adverse reaction or suspected adverse reaction t hat, had it occurred in a more 
severe form, might have caused death. 
An AE or suspected adverse react ion is considered unexpected if  it is not listed in the current 
investigator brochure or is not listed at the specificity or se verity that has been observed. 
[IP_ADDRESS] Reporting SAEs 
In agreeing to the provisions of this protocol, the Investigato r accepts all legal responsibilities 
for AE identification, documentation, grading, assignment of ca usality, and prompt 
notification of SAEs to Pearl Phar macovigilance or designee. Al l SAEs must be reported to 
Pearl Pharmacovigilance or de signee no later than 24 hours afte r the Investigator 
recognizes/classifies the event as an SAE. All SAEs should be d ocumented and reported 
using the eCRF. At a minimum , a description of the event and the Investigator’s judgment of 
causality must be provided at the time of the initial report us ing the appropriate form (eg, 
SAE Report Form). After the initial report, as necessary, the I nvestigator must provide any 
additional information on an SAE t o Pearl Pharmacovigilance or designee within 2 working 
days after receiving the information. Follow-up information wil l be a detailed written report 
that may include copi[INVESTIGATOR_247401], case reports, auto psy reports, and other pertinent 
documents. 
For subjects discontinuing study drug and withdrawing from the study, all AEs/SAEs will be 
collected through the 5- to 7-day follow up telephone call. 
Post-study SAEs following the last dose of study drug must be r eported to Pearl 
Pharmacovigilance as described in Section [IP_ADDRESS] .  
The Investigator is responsible for continuing to report any ne w or relevant follow up 
information that s/he learns about the SAE. 
[IP_ADDRESS] Supplemental Investigations of SAEs 
The Investigator and supporting personnel responsible for subje ct care should discuss with 
the Sponsor Medical Monitor or designee any need for supplement al investigations of SAEs. 
If additional assessments are c onducted, results must be report ed to the Sponsor. If a subject 
dies during study participation and if a post mortem examinatio n is performed, a copy of the 
autopsy report should be submitted to the Sponsor. 
[IP_ADDRESS] Post-Study Follow-up of AEs 
Any AE s that are unresolved at the subject’s last AE assessment in the study are followed up 
by [CONTACT_96770], but wit hout further recording in the 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428757] with ongoing 
AE(s)/SAE(s) at the end of the study, if judged necessary. 
[IP_ADDRESS] Notification of Post-Treatment SAEs 
Investigators are not obligated to actively follow subjects aft er completion of the study. 
However, if the Investigator becomes aware of a post-treatment SAE occurring within the [ADDRESS_428758] be reported to the 
Sponsor no later than 24 hours after the Investigator recognize s/classifies the event as an 
SAE. 
[IP_ADDRESS] IRB/IEC Notification of SAEs 
The Investigator is responsible for promptly notifying her/his IRB/IEC of all SAEs, including 
any follow-up information, occurring at their site and any SAE regulatory report, including 
any follow-up reports received from the Sponsor. Documentation of IRB/IEC submission 
must be retained for each safety report. The Investigator is al so responsible for notifying the 
Sponsor if their IRB/IEC requires revisions to the ICF or other  measures based on its review 
of an SAE Report. 
[IP_ADDRESS] Health Authority Safety Reports 
The Sponsor or its representatives will submit a safety report to the appropriate regulatory 
agencies for any suspected adverse reaction that is both seriou s and unexpected within the 
timeframe specified by [CONTACT_22105]. 
The Sponsor or its representatives will send copi[INVESTIGATOR_345213] l studies. Safety reports must 
also be submitted to the appropriate IRBs/IECs as soon as possi ble. Documentation of 
submission to the IRB/IEC must be retained for each safety repo rt. 
7.7.[ADDRESS_428759] clinical judgment in treatin g the overdose, and the Sponsor 
Medical Monitor should be contact[INVESTIGATOR_530]. Investigators should refer  to the relevant document(s) 
for detailed information regarding warnings, precautions, contr aindications, AEs, and other 
significant data pertaining to the study drug(s) being administ ered. Such document(s) may 
include, but are not limited to: t he investigator brochure for BGF MDI and approved product 
labeling for open-label products. 
7.7.[ADDRESS_428760] be 
reported to the Sponsor within 24 hours of learning of its occu rrence. The pregnancy should 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 48 of 96 be followed in its entirety to ascertain outcome, including spo ntaneous or voluntary 
termination, details of the birth, a nd the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or  newborn complications. Pregna ncy should be recorded on a 
Paper Pregnancy Report Form and r eported by [CONTACT_345277]. Pregnancy follow-up should be recorded on the same pr egnancy paper form and 
should include possible relationship to the study drug in respo nse to the pregnancy outcome. 
Any SAE experienced during preg nancy must be reported on the SA E Report Form. 
7.7.[ADDRESS_428761] agree to use a doubl e barrier method of 
contraception (condom with sper micide) from the first dose of s tudy drug until [ADDRESS_428762]'s partner becomes pregnant during the course of the stu dy, it must be reported to the 
Sponsor within [ADDRESS_428763] be implemented by [CONTACT_737], if 
instructed to do so by [CONTACT_154034], in a time frame that is compatible with the subjects’ well -
being. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 49 of 96 8 STUDY ACTIVITIES 
A schedule of events is provided in Table 8-1 . Detailed schedules of inpatient assessments on 
Visit 3 (Day 1) and Visit 5 (Day 8) are provided in Table 8-2  and Table 8-3 , respectively. 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 50 of 96 Table 8-1 Schedule of Events for Screening, Treatment, and Foll ow-up 
 Screening Treatment Perioda Follow up 
Visit 1 Visit 2 
Clinic Admission Visit 3 Visit 4 
Clinic Admission Visit 5 Telephone 
Follow up 
Procedure/Assessment  D a y s  - [ADDRESS_428764] dose 
Informed consent X      
Inpatient admission  X  X   
Medical history X      
Demographics X      
Physical examination X X   X  
Spi[INVESTIGATOR_345214] X X  X   
Vital signs (BP, heart rate) X X  X X  
Chest x-rayc X      
Eligibility reviewd X X X X X  
Subject enrollment number   X    
Placebo MDI usage demonstration/practicee Xf Xf Xf Xf Xf  
12-lead ECG X X   X  
Clinical laboratory testingg X X   X  
AEs Xh Xh X X X X 
Concomitant medications X X X X X X 
Urine drug screen X X  X   
Alcohol breathalyzer test X X  X   
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 51 of 96 Table 8-1 Schedule of Events for Screening, Treatment, and Foll ow-up 
 Screening Treatment Perioda Follow up 
Visit 1 Visit 2 
Clinic Admission Visit 3 Visit 4 
Clinic Admission Visit 5 Telephone 
Follow up 
Procedure/Assessment  D a y s  - [ADDRESS_428765] (females only)i X X  X   
PK assessmentj   X X X  
Dispense/collect Ventolin HFAk X X X  X  
Dispense/collect study drug MDI   X  X  
Study drug administrationl   Xm X Xm  
Dispense/collect/review diaryn   X X   
Clean study drug MDI deviceo    X   
Inpatient discharge   Xp  Xq  
Abbreviations: AE=adverse event; BID=twice daily; BP=blood pres sure; COPD=chronic obstructive pul monary disorder; ECG=electroc ardiogram; FEV 1=forced 
expi[INVESTIGATOR_3741] 1 secon d; FVC=forced vital capacity; hCG=human chorionic gonadotropin; HFA=hydrofluoroalkane; MDI=me tered dose inhaler; 
PK=pharmacokinetic ; SAE=serious adverse event. 
a Sites must call subjects for morning and evening study drug adm inistration confirmation on Days [ADDRESS_428766] be ≥50% and <80% predicted  and pre-bronchodilator FEV 1/FVC must be <0.[ADDRESS_428767] –bronchodilator 
assessments to confirm the diagnosis of COPD (defined as FEV 1 <80% predicted and FEV 1/FVC<0.70) must be performed to confirm the diagnosis of 
COPD if not documented and available in the [ADDRESS_428768] dose w ill be recorded as medical histo ry. 
i For all women, obtain serum hCG at Screening and urine hCG ther eafter. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 52 of 96 Table 8-1 Schedule of Events for Screening, Treatment, and Foll ow-up 
 Screening Treatment Perioda Follow up 
Visit 1 Visit 2 
Clinic Admission Visit 3 Visit 4 
Clinic Admission Visit 5 Telephone 
Follow up 
Procedure/Assessment  D a y s  - [ADDRESS_428769] dose 
j PK samples will be collected predo se on Days 1 (morning dose), 7 (evening dose), and 8 (morning dose). 
k Ventolin HFA will dispensed at Visits 1, 2, and [ADDRESS_428770]’s follow -up phone call at least [ADDRESS_428771] administration of study drug. 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 53 of 96 Table 8-2 Timing of Assessments on Day 1 (Visit 3) 
 Time Relative to Drug Administration 
Procedure -60 
min 0 
hr 2 
min 6 
min 20 
min 40 
min 1 
hr 2 
hrs 4 
hrs 8 
hrs 10 
hrs 12 
hrs 18 
hrs 24 
hrsa 
PK blood draw  Xb  X X X X X X X X X X X X 
Placebo MDI usage 
demonstration/practice  X              
Administration of study drugc  X            Xd 
Adverse events X X X X X X X X X X X X X X 
Concomitant medication X X X X X X X X X X X X X X 
a The 24-hour post-dose assessment occurs on Day 2. 
b Within [ADDRESS_428772]- dose PK sample has been collected and before discharge from the  clinic. 
 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 54 of 96 Table 8-3 Timing of Assessments on Day 8 (Visit 5) 
Procedure Time Relative to Drug Administration 
-60 
min 0 
hr 2 
min 6 
min 20 
min 40 
min 1 
hr 2 
hrs 4 
hrs 8 
hrs 10 
hrs 12 
hrs 
PK blood draw Xa  X X X X X X X X X X 
Placebo MDI usage demonstration/practice X            
Administration of study drugb  X           
12-lead safety ECG X            
Clinical laboratory tests Xc            
Vital signs X           X 
Physical examination   Xd 
Adverse events X X X X X X X X X X X X 
Concomitant medication X X X X X X X X X X X X 
a Within 60 minutes prior to dosing.  
b Study drug will be administered by [CONTACT_345267]. A final sin gle-dose administration of study drug will occur on the morning  of Day 8. 
c Complete clinical laboratory testing - chemistry and hematology  (includes glucose and potassium) fasting required. 
d Complete any time prior to discharge. 
 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 55 of 96 8.1 Screening Visit 1 (Screening, Day -28 to Day -2) 
After obtaining written and signed informed consent, the follow ing procedures and 
assessments will be performed during the Screening period and r esults will be documented in 
the eCRF and/or source documents: 
• Obtain informed consent (obtain first, before other study proce dures) 
• Record demographics and relevant medical history 
• Perform physical examination 
• Record smoking status 
• Obtain vital signs 
• Practice Placebo MDI usage and de monstrate proper technique 
• Conduct spi[INVESTIGATOR_345215]-bronchodilator spi [INVESTIGATOR_345216] (post-bronchodil ator FEV 1 <80% 
predicted and FEV 1/FVC <0.70) in the past 12 months 
• Obtain 12-lead ECG 
• Collect blood and urine samples for clinical laboratory evaluat ions (hematology, 
chemistry, and urinalysis) 
• Document concomitant medications 
• Perform urine drug test 
• Perform alcohol breathalyzer test 
• Perform serum pregnancy test (women only) 
• Obtain chest x-ray if needed 
• Review eligibility criteria 
• Dispense Ventolin HFA 
• Document AEs (Note: AEs that occur prior to dosing will be reco rded as medical 
history unless the event meets the definition of an SAE as defi ned in Section 7.7.10 ) 
 
8.2 Visit 2 (Admission to Clinic, Day -1) 
The following study activities and assessments will be performe d on Day -1, and results will 
be documented in the eCRF  and/or source documents: 
• Perform physical examination 
• Record smoking status 
• Obtain vital signs 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 56 of 96 • Obtain 12-lead ECG 
• Collect blood and urine samples for clinical laboratory evaluat ions (hematology, 
chemistry, and urinalysis) 
• Document AEs (Note: AEs that occur prior to dosing will be reco rded as medical 
history unless the event meets the definition of an SAE as defi ned in Section 7.7.10 ) 
• Document concomitant medications 
• Perform urine drug test 
• Perform alcohol breathalyzer test 
• Perform urine pregnancy test (women only) 
• Review eligibility criteria 
• Admit subject to the clinic 
• Practice Placebo MDI usage a nd demonstrate proper technique 
• Dispense Ventolin HFA (if needed) 
 
8.3 Visit 3 (Day 1/Day 2 of the Treatment Period) 
The following study activities and assessments will be performe d on Day 1 and Day 2, and 
results will be documented in the  eCRF and/or source documents:  
• Review eligibility criteria 
• Obtain subject enrollment number 
• Practice Placebo MDI usage and de monstrate proper technique 
• Document AEs (Note: AEs that o ccur prior to dosing will be reco rded as medical 
history unless the event meets the definition of an SAE as defi ned in Section 7.7.10 ) 
• Document concomitant medications  
• Collect pre-dose PK samples per Table 8-2  
• Administer study drug; a single  dose of study drug will be admi nistered by [CONTACT_345278] (refer to Section 6.5 for details regarding study drug dispensing and 
administration). 
• Collect post-dose PK samples per Table 8-[ADDRESS_428773]-dose sample will be 
collected on the morning of Day 2. 
• Dispense study drug MDI and Ventolin HFA 
• Administer morning dose of study drug in the clinic on Day [ADDRESS_428774]-
dose PK sample has been collecte d and before discharge from the  clinic 
• Schedule telephone calls with s ubjects for dose administration confirmation 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 57 of 96 • Schedule Visit 4 
• Dispense diary 
• Discharge subject on Day [ADDRESS_428775] (Days 2 to 7 of the Treatment Period) 
• Call subjects for morning and evening dose administration confi rmation. 
Note:  Dosing must be scheduled relative to the subject’s first morning dose in clinic 
on Day 1 (Visit 3). Subjects must be  advised that subsequent mo rning study drug 
dosing must occur at approximately the same time every day and that evening dosing 
should occur as close as possible to 12 hours from the time of morning dosing. 
 
8.5 Visit 4 (Day 7) 
The following study activities and assessments will be performe d on Day 7, and results will 
be documented in the eCRF  and/or source documents: 
• Document AEs 
• Document concomitant medications 
• Collect diary and review with subject 
• Record smoking status 
• Obtain vital signs 
• Confirm subject’s eligibility to continue in the study  
• Practice Placebo MDI usage and de monstrate proper technique 
• Perform urine drug test 
• Perform alcohol breathalyzer test 
• Perform urine pregnancy test (women only) 
• Admit the subject to the clinic 
• Collect PK sample within 60 minutes prior to evening dose  
• Administer the evening dose of study drug as close as possible to 12 hours from the 
time of morning dose 
• After the evening dose, study site staff should wash the study drug device and dry for 
approximately 12 hours overn ight per instructions in Appendix 2  
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 58 of 96 8.6 Visit 5 (Day 8) 
The following study activities and assessments will be performe d on Day 8, and results will 
be documented in the eCRF  and/or source documents: 
• Perform physical examination 
• Obtain vital signs 
• Obtain 12-lead ECG 
• Collect blood samples and urine for clinical laboratory evaluat ions (hematology, 
chemistry, and urinalysis) 
• Confirm subject’s eligibility to continue in the study  
• Document AEs 
• Document concomitant medications  
• Practice Placebo MDI usage and de monstrate proper technique 
• Collect pre-dose PK samples per Table 8-3  
• Administer study drug; a single  dose of study drug will be admi nistered by [CONTACT_345278] (refer to Section 6.5 for details regarding study drug dispensing and 
administration). 
• Collect post-dose PK samples per Table 8-3  
• Collect study drug MDI and Ventolin HFA 
• Restart subject’s COPD medications  after all assessments are completed 
• Schedule follow-up telephone call 
 
After all scheduled protocol-spe cified assessments are complete , and safety data, including 
vital signs, have been reviewed b y the Investigator, the subjec t will be discharged from the 
clinic. 
8.[ADDRESS_428776] administration on V isit 5 (Day 8). Subjects will be 
asked about any new or ongoing AEs, and any new concomitant med ication. This will be 
documented appropriately in the s ubject source documents and eC RFs. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428777] populations will be evaluated during this study and  are defined as follows: 
• PK Population: All treated subjects who have sufficient data to reliably calcu late at 
least [ADDRESS_428778]  major protocol deviations.  Subjects will be 
analyzed according to treatment received. 
• Safety Population: All subjects who receive at least 1 dose of study drug. 
 
Safety and tolerability analys es will be performed on data from  all subjects in the Safety 
Population. 
Pharmacokinetic analysis will be performed using the PK populat ion. 
9.3 Demographics and Baseline Characteristics 
Demographic information will include month/year of birth, gende r, ethnicity, and race. 
Demographics and baseline charact eristics will be summarized de scriptively for both the 
Safety and PK Populations. Height and weight, which are conside red baseline characteristics 
and documented as part of the ph ysical examination performed at  Screening, will be reported 
with the demographic information. 
9.[ADDRESS_428779] day (Day 1) and using pre-defined post do se serial blood draws over [ADDRESS_428780] dose (Day 8) will include the following: 
• Cmax 
• AUC 0-12 
• tmax 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 60 of 96 The following PK parameters will be calculated at Day 1 only: 
• AUC 0-tlast 
• AUC 0-∞ 
• t1/2 
• CL/F 
• Vd/F 
• λz 
 
The following will be derived based on ratios of Day 8 values t o Day 1 values: 
• Accumulation ratio for C max (RAC [C max]) 
• Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) 
• Linearity ratio (Rlin [AUC 0-12/AUC 0-∞]) 
 
Other PK parameters may be calculated, as appropriate.  
Descriptive statistics for plasma concentrations of budesonide,  glycopyrronium, and 
formoterol by [CONTACT_345279]-normal 
scales using the PK Population. Individual plasma concentration  at each nominal and actual 
time point for each Day will be listed by [CONTACT_345280]. 
All budesonide, glycopyrronium, and formoterol PK parameters wi ll be presented by [CONTACT_765] 
(Visit 3 [Day 1] or Visit 5 [Day 8]) with number of measurement s, number of subjects with 
non-missing data (n), mean, s tandard deviation, coefficient of variation (CV%), median, 
minimum, maximum, geometric me an, and geometric CV%. For t max, the geometric mean 
and the CV% will be omitted, and only the number of observation s (n), median, minimum 
and maximum will be provided.  
To estimate the RAC values and Rl in, natural-log transformed AU C0-12, AUC 0-∞, and C max of 
budesonide, glycopyrronium, and fo rmoterol between Day [ADDRESS_428781] square mean (LSM) for Day 8 to Day 1 and the co rresponding 90% 
confidence interval (CI) will be  determined by [CONTACT_257953] t he mean difference between 
Day 8 and Day 1 and the associated CI (on the logarithm scale).  The estimated ratio of 
geometric LSM and its corresponding 90% CI will be an estimate of RAC or Rlin with the 
90% CI. The residual variance component from the model estimati ng Rlin will provide an 
estimate of intra-subject variability. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 61 of 96 If the effective rate of drug a ccumulation is estimable, the ti me to reach steady state will be 
estimated for each analyte using th e methodology of Panebianco and Maes 
(Panebianco 2009). 
9.5 Safety Analyses 
Safety data will be summarized and listed. The safety of BGF MD I will be assessed from AE 
reporting including SAE reporting, vital signs (BP, heart rate) , clinical laboratory values 
(hematology, chemistry, and urinalysis), and findings from 12-l ead ECGs. The incidence of 
AEs and SAEs will be tabulated. Summary statistics of assessed laboratory values and vital 
signs by [CONTACT_345281]. Subje cts with out-of-range values 
of 12-lead ECGs will be listed. 
9.6 Randomization 
Not applicable. 
9.7 Determination of Sample Size 
This study is descriptive in nature. The planned sample size of  approximately 30 enrolled 
subjects is selected to provide approximately 24 completers for  assessment of the single- and 
multiple-dose PK of BGF MDI in subjects with COPD. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428782] of the Study and IRB or IEC Approval 
The study will be conducted in accordance with Good Clinical Pr actice (GCP), Declaration 
of Helsinki, concerning medical research in humans (Ethical Pri nciples for Medical Research 
Involving Human Subjects), and regulatory requirement if applicable.’  
The Investigator (or The Sponsor, w here applicable) is responsi ble for ensuring that this 
protocol, the site’s ICF, and any other information that will be  presented to potential subjects 
(eg, advertisements or informati on that supports or supplements  the ICF) are reviewed and 
approved by [CONTACT_19821]/IEC. The Investigator agrees to  allow the IRB/IEC direct 
access to all relevant documents. The IRB/IEC must be constitut ed in accordance with all 
applicable regulatory requirements. 
The Sponsor will provide the Investigator with relevant documen t(s)/data that are needed for 
IRB/IEC review and approval of the study. If the protocol, the ICF, or any other information 
that the IRB/IEC has approved for presentation to potential sub jects is amended during the 
study, the Investigator is responsible for ensuring the IRB/IEC  reviews and approves, where 
applicable, these amended documents. The Investigator must foll ow all applicable regulatory 
requirements pertaining to the use of an amended ICF including obtaining IRB/IEC approval 
of the amended form before new subjects consent to take part in  the study using this version 
of the form. The IRB/IEC approval  of the amended ICF/other info rmation and the approved 
amended ICF/other information mus t be forwarded to The Sponsor promptly. 
10.[ADDRESS_428783] be reviewed 
and approved by [CONTACT_1201]/IEC and the Sponsor prior to initiation  of the study. 
The Investigator will be responsible for obtaining written info rmed consent from potential 
subjects prior to any study-specific screening and entry into t he study. The subject will be 
provided with [ADDRESS_428784] provide evidence of adequate lic ensure or accreditation 
according to the prevailing re gulations in that state and/or co untry. Reference values and/or 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428785] be 
notified promptly in writing of any changes occurring in refere nce values during the course 
of the study. 
10.5 Confidentiality 
10.5.1 Confidentiality of Data 
By [CONTACT_12570], the Investigator affirms to the Spons or that information furnished to 
the Investigator by [CONTACT_345282] e and such information will 
be divulged to the IRB/IEC, or simi lar or expert committee; aff iliated institution; and 
employees only under an appropri ate understanding of confidenti ality with such board or 
committee, affiliated institution and employees. Data generated  by [CONTACT_345283] I nvestigator, except to the exte nt that it is included in a 
publication. 
10.5.[ADDRESS_428786]/Patient Records 
By [CONTACT_12570], the Investigator agrees that the Spon sor (or representative), 
IRB/IEC, or Regulatory Agency representatives may consult and/o r copy study documents in 
order to verify worksheet/case r eport form data. By [CONTACT_345284], the 
subject/patient agrees to this process. If study documents will  be photocopi[INVESTIGATOR_345217]/case report form information, th e subject/patient will be 
identified by [CONTACT_19494]; full names/initials will be mas ked prior to transmission to the 
Sponsor. In addition, the Investi gator agrees to treat all subj ect data used and disclosed in 
connection with this study in accordance with all applicable la ws, rules and regulations. 
10.[ADDRESS_428787] the 
site, including conducting on-sit e visits. The extent, nature, and frequency of on-site visits 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 64 of 96 will be based on such considerations  as the study objective and /or endpoints, the purpose of 
the study, study design complexity, and enrollment rate. 
During these contacts, the monitor will: 
• Check the progress of the study 
• Review study data collected 
• Conduct source document verification 
• Identify any issues and address their resolution 
 
This will be done in order to verify that the: 
• Data are authentic, accurate, and complete 
• Safety and rights of subjects are being protected 
• Study is conducted in accordance with the currently approved pr otocol (and any 
amendments), GCP, and  all applicable regulatory requirements 
 The Investigator agrees to allow the monitor direct access to a ll relevant documents and to 
allocate his/her time and the time of his/her staff to the moni tor to discuss findings and any 
relevant issues 
Upon completion of the study, the monitor will conduct the foll owing activities in 
conjunction with the Investigator or site staff, as appropriate : 
• Return of all study data to the Sponsor 
• Data queries 
• Accountability, reconciliation, a nd arrangements for unused inv estigational 
product(s) 
• Review of site study records for completeness 
 
After the final review of the study files, the files should be secured for the appropriate time 
period as specified in Section 10.9. The Investigator will also permit inspection of the study 
files by [CONTACT_1034]’ Quality Assurance auditors, and author ized representatives of the Food 
and Drug Administration (FDA) or other applicable regulatory ag encies. 
10.[ADDRESS_428788] be maintained for rev iew by [CONTACT_1034]' quality 
assurance auditors and by [CONTACT_345285] . The period of time these 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428789] be maintained is governed by [CONTACT_345286]. The Sponsor or its 
designee will inform the Investigator when these documents may be destroyed. The Sponsor 
or it’s designee should contact [CONTACT_91004] [ADDRESS_428790] related to this protocol to allow the Spons or to make alternate storage 
arrangements. 
10.10 Financial Disclosure 
The Investigator or sub-Investigators named on FDA Form 1572 wi ll need to complete a 
financial disclosure form prior t o study initiation, at any tim e during the study execution if 
new information needs to be disclosed, and for 1 year after stu dy completion. Investigators 
should make the IRB/IEC aware of any financial interests that t he Investigator has in the 
investigational product. 
10.11 Investigator’s Final Report  
Shortly after completion of the  Investigator's participation in  the study, the Investigator will 
submit an end of study summary report to the Sponsor. 
10.12 Publication Policy 
The Sponsor intends to publish the results of all of the clinic al studies that it sponsors in 
compliance with the Declarati on of Helsinki (http://www.wma.net /en/10home/index.html). 
Consistent with the recommendations of the editors of several l eading medical journals, the 
International Committee of Medical Journal Editors (ICMJE), aut horship of publications 
resulting from Sponsor-sponsored studies should fairly recogniz e the activities of those that 
have made a significant contribution to the study. In addition,  the Sponsor recognizes and 
adheres to the precepts of the I nternational Society for Medica l Publication Professionals 
(ISMPP), which provides guidan ce to the preparation of publicat ions, disclosure of conflicts 
of interest, and the protection of intellectual property. Thus,  it is anticipated that authorship 
will reflect the contribution m ade by [CONTACT_22127], th e Investigators, and others 
involved, such as statisticians. 
In recent years, issues about conflicts of interest and accurac y of the study data have been 
raised in the medical press. Accordingly, the Sponsor has devel oped publication guidelines as 
described below: 
1. Responsibility: Each Principal Investigator [INVESTIGATOR_345218]. The Sponsor (or its r epresentative) is responsible 
for the accuracy of the data entered into the study databases a nd for the accuracy of the 
analyses conducted. 
2. Authorship and Publication Committee: The Sponsor, in collabora tion with the 
Investigators, will establish t he appropriate authorship and re sponsibility for drafting 
study documents in accordance with the principles of the ICMJE and ISMPP. It is 
anticipated that a publication c ommittee will be formed to assu me oversight of these 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 66 of 96 activities. All manuscripts will be reviewed and agreed upon be fore submission for 
publication by [CONTACT_15064]. 
3. Sponsor Review of External Manuscrip ts: Consistent with the fir st bullet point, drafts of 
any and all publications or presentations that may arise from t his study must be submitted 
at least [ADDRESS_428791] facts and to 
represent its opi[INVESTIGATOR_6153], or the  opi[INVESTIGATOR_345219], if these differ with 
the proposed publication. 
4. Confidentiality: Investigators will conduct all interactions wi th the Sponsor and with 
third parties consistent with the executed confidentiality agre ements. While publication, 
by [CONTACT_7586], presents the critica l scientific data in a public  forum, some information 
(such as future plans, results of nonclinical studies, or chemi cal formulae) may still need 
to remain confidential. 
5. Medical Journal Review: Consistent with the intention of the Sp onsor to publish the 
study in a fair and accurate ma nner, the Sponsor supports dilig ence in the publication 
review process of medical journals . Accordingly, upon request, all pertinent study data 
and information will be made available as supplemental informat ion for journal editors 
and reviewers to evaluate and a udit, eg, protocol and amendment s, data tabulations. The 
journal and reviewers will need to make arrangements to maintai n the confidentiality of 
such supplemental information, where relevant, and the Sponsor will make suitable 
arrangements to ensure that the identity of journal reviewers i s kept confidential. Records 
will be maintained of reviewers and the respective documents an d datasets that were 
reviewed by [CONTACT_345287]. 
6. Reporting of Clinical Trial Results: To provide transparency in  the conduct and reporting 
of randomized clinical trials , the Sponsor reports clinical fin dings based on the guidance 
of The CONsolidated S tandards of Reporting Trials Statement (Mo hler 2012) and a 25-
item checklist, which is intended to improve the reporting of a  randomized controlled 
study; facilitate reader unders tanding of the study design, con duct, analysis and 
interpretation; and support their a bility to assess the validit y of its results.  
7. Internet Clinical Trial Listing: In addition, also consistent w ith the recommendations of 
the ICMJE, the Sponsor will make  available appropriate informat ion regarding the study 
via the internet. This will include registration and listing of  the study on 
www.clinicaltrials.gov, the US National Institutes of Health li sting of clinical trials. Per 
[COMPANY_008] policy, The Sponsor posts clinical study protocols for public viewing when 
a manuscript is published in a medical journal. Prior to being made public, the protocol is 
reviewed by [CONTACT_345288]. 
 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428792] 
Celli B, MaNee W, Agusti A, et al. Standards for the diagnosis and treatment of subjects with 
COPD: a summary of the ATS/ERS position paper. Eur Respir J. 20 04;23:932-946. 
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for 
Diagnosis, Management, and Prevention of COPD-2017. http://www. goldcopd.org/. 
Accessed 31 January 2017. 
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of s pi[INVESTIGATOR_038]. Eur Respir J. 
2005;26:319 338. 
Mohler, D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanati on and Elaboration: 
updated guidelines for reporting parallel group randomised tria ls. J Clin Epi[INVESTIGATOR_345220] 
2010;63:e1-37. Erratum in J Clin Epi[INVESTIGATOR_345220]. 2012;65:351. 
Panebianco DL, Maes A. Estimating time to steady state using th e effective rate of drug 
accumulation. Pharm Stat. 2011;10:27-33. 
SYMBICORT® (budesonide and formoterol fumarate dehydrate) inhal ation aerosol 
[package insert]. Wilmington, DE. [COMPANY_008]; 2017. 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 68 of 96 12 APPENDICES 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 69 of 96 Appendix 1 Dose Indicator Reading 
130 Count (Actuation) Version Shown  
 
If your dose 
indicator 
display looks 
like this record 
120+    
If your dose 
indicator 
display looks 
like this record 
[ADDRESS_428793]  
0   
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010018-[ADDRESS_428794] Instructions for Use of BGF MDI and Placebo 
MDI 
How do I store the Inhaler? 
• The inhaler should be stored below 25°C (77°F) in a dry place. Excursions permitted 
up to 30°C (86°F). 
• The contents of the canister are under pressure. Do not punctur e or throw the canister 
into a fire or incinerator. Do not use or store it near heat or  open flame. Storage 
above 120ºF may cause the canister to burst. 
• Keep the product and all medici nes out of the reach of children . 
 
For Oral Inhalation Only 
Parts of the Inhaler: 
• The parts of your inhaler are seen in Figure 1 . 
 
Figure 1 
 
 
• The Dose indicator  lets you know about how many puffs are left in your inhaler an d 
is the part of the inhaler that is pressed to dispense a puff o f medication.  See Figure 
1. 
• The Dose indicator  should be pointing just to the right of 120 when your inhaler is 
new.  See Figure 1 . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010018-00 Version 1.0 
  
Confidential and Proprietary Page 71 of 96 • The Dose indicator  has numbers for every 20 puffs.  The Dose indicator  display 
will move after every tenth puff.   
• For example, if the Dose indicator  is pointing to 120 ( see Figure 2a ) and you take 
10 puffs it will move between 120 and 100.  This means that the re are 110 puffs of 
medicine left ( see Figure 2b ).  After 10 more puffs are used, the Dose indicator  
pointer will move to the number 100 .  This means that there are  100 puffs of 
medicine left ( see Figure 2c ). 
• The Dose indicator  number will continue to change after every 20 puffs. 
• When the number in the Dose indicator  window changes to 20 and the color behind 
the number changes to red, this means that there are only 20 pu ffs left in your 
inhaler.  See Figure 2d . 
 
Figure 2 
 
 
Preparing the Inhaler for Use: 
The inhaler comes in a foil pouch that contains a drying packet  (desiccant). 
• Take the inhaler out of the foil pouch. 
• Throw away the pouch and the drying packet.  Do not eat or inha le the contents of 
the drying packet.   
• Remove the Cap from the Mouthpi[INVESTIGATOR_345221] 3 .   
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 72 of 96 Figure 3 
 
 
• Prime the inhaler before you use it for the first time. 
 
Priming the Inhaler: 
• Check inside the Mouthpi[INVESTIGATOR_345222]. 
• Hold the Actuator  with the Mouthpi[INVESTIGATOR_345223] 4a . 
• Shake the inhaler well before each puff. 
• Push down fully on the center (not ‘off center’) of the Dose indicator  on top of the 
Canister (see Figure 1)  until the Canister  stops moving in the Actuator  to release a 
puff from the Mouthpi[INVESTIGATOR_345221] 4b .  Note: It is normal to hear a soft 
click from the dose indicator a s it counts down during use. 
• Repeat this priming step 3 more times for a total of 4 times, s haking the inhaler each 
time before you press it. 
• After completing the [ADDRESS_428795] from your 
face. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010018-00 Version 1.0 
  
Confidential and Proprietary Page 73 of 96 Figure 4 
 
 
Using the Inhaler: 
Your dose of medicine comes from 2 puffs  from the inhaler. 
Refer to Figure 5  for Step 1 through Step 8. 
• Step 1 : Remove the Cap from the Mouthpi[INVESTIGATOR_13959] . 
• Step 2 : Shake the inhaler well before each puff. 
• Step 3 : While holding the inhaler with the Mouthpi[INVESTIGATOR_345224] a s much air from your lungs as possible. 
• Step 4 : Close your lips around the Mouthpi[INVESTIGATOR_345225] . 
• Step 5 : Take a deep breath in (inhale) slowly through your mouth whil e pressing 
down firmly on the center (not 'off center') of the Dose indicator  until the Canister  
stops moving in the Actuator  and a puff has been released. Then, stop pressing the 
Dose indicator.  
• Step 6 : When you have finished breathing in, remove the Mouthpi[INVESTIGATOR_345226] 10 seconds or as long as comfort able.   
• Step 7 : Then, breathe out normally.   
 
Take your second puff of medicine by  [CONTACT_345289] 2 through S tep 7.   
• Step 8 : Replace the Cap back on the Mouthpi[INVESTIGATOR_13959] . 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 74 of 96 Figure 5 
 
 
How to clean the Inhaler: 
It is very important to keep your inhaler clean so medicine wil l not build-up and block the 
spray through the Mouthpi[INVESTIGATOR_13959] . See Figure 6. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 75 of 96 Figure 6 
 
 
The Canister  should be gently pulled from the top of the Actuator  once a week and the 
Actuator  cleaned. Do not clean the Canister or let it get wet.  
• Step 1 : Pull the Canister  out of the Actuator  as shown in Figure 7. 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 76 of 96 Figure 7 
 
 
• Step 2 : Set the Canister  aside where it will not get wet. 
• Step 3 : Take the Cap off the Mouthpi[INVESTIGATOR_13959] . 
• Step 4 : Rinse the Actuator  through the top with warm running water for 30 seconds. 
Then rinse the Actuator  again through the Mouthpi[INVESTIGATOR_13959]  (see Figure 8 ).  
 
Figure 8  
 
• Step 5 : Shake all of the water droplets out of the Actuator . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 77 of 96 • Step 6 : Look in the Actuator  and the Mouthpi[INVESTIGATOR_345227]. 
 
Repeat Step 4  through Step 6 , until the Actuator  and the Mouthpi[INVESTIGATOR_345228]. 
• Step 7 : Let the Actuator  dry completely, such as overnight as shown in Figure 9. Do 
not put the Canister  back into the Actuator  if it is still wet. 
 
Figure 9  
 
 
Reassembly of the Inhaler and Instructions for Use after Cleani ng: 
• After the Actuator  is completely dry, gently press the Canister  down in the 
Actuator  as shown in Figure [ADDRESS_428796] enough to cause a puff to be released. 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 78 of 96 Figure 10 
 
• Re-prime your inhaler 2 times after each cleaning. 
• Hold the Actuator  with the Mouthpi[INVESTIGATOR_345223] 4 . 
• Shake the inhaler well before each puff. 
• Push down fully on the center (not 'off center') of the Dose indicator  on top of the 
Canister  until the Canister  stops moving in the Actuator  to release a puff from the 
Mouthpi[INVESTIGATOR_13959] . 
• Repeat this re-priming step 1 m ore time for a total of 2 times.  
• After re-priming your inhaler 2 times, your inhaler is now read y to use. 
  

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428797] left. The number 
shows through a window in the back of the actuator. See Figure B . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 80 of 96 Figure B 
 
 Figure B 
• The counter starts at either [ADDRESS_428798]. 
The number will count down by 1 each time you spray the inhaler . The counter will 
stop counting at 000. 
• Do not try to change the numbers o r take the counter off the me tal canister. The 
counter cannot be reset, and it is  permanently attached to the canister. 
• The blue plastic actuator sprays  the medicine from the canister . The actuator has a 
protective cap that covers the mouthpi[INVESTIGATOR_13959]. See Figure A . Keep the protective cap on 
the mouthpi[INVESTIGATOR_345229] r is not in use. The strap keeps  the cap attached to 
the actuator. 
• Do not use the actuator with a canister of medicine from any other inh aler. 
• Do not use a VENTOLIN HFA canister with an actuator from any other inh aler. 
 
Before you use VENTOLIN HFA for the first time, you must prime the inhaler so that 
you will get the right amoun t of medicine when you use it. 
To prime the inhaler, take the cap off the mouthpi[INVESTIGATOR_345230]. Then spray 
the inhaler [ADDRESS_428799] from your face . See Figure C . Avoid spraying in eyes . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 81 of 96 Figure C 
 
 Figure C 
• Shake and spray the inhaler like this [ADDRESS_428800] from your face. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 82 of 96 How to use your VENTOLIN HFA inhaler: 
Follow these steps every time you use VENTOLIN HFA. 
Step 1.  Make sure the canister fits firmly in the actuator. The counte r should show through 
the window in the actuator. 
Shake the inhaler well  before each spray. 
Take the cap off the mouthpi[INVESTIGATOR_345231]. Look inside th e mouthpi[INVESTIGATOR_345232], and take out any you see. 
Step 2.  Hold the inhaler with the mouthpi[INVESTIGATOR_280821]. See Figure E . 
Figure E 
 
 Figure E 
Step 3 . Breathe out through your mouth and push as much air from your  lungs as you can. 
Put the mouthpi[INVESTIGATOR_345233].  See Figure F . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428801]. 
Cleaning your VENTOLIN HFA inhaler: 
Clean your inhaler at least 1 time each week. You may not see a ny medicine build-up on the 
inhaler, but it is important to keep it clean so medicine build -up will not block the spray. See 
Figure G . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
  
 
Confidential and Proprietary Page 84 of 96 Figure G 
 
 
Figure G 
Step 8 . Take the canister out of the actuator, and take the cap off t he mouthpi[INVESTIGATOR_13959]. The strap 
on the cap will stay attached to the actuator. 
Step 9 . Hold the actuator under the fau cet and run warm water through  it for about 30 
seconds. See Figure H . 
Figure H 
 
 Figure H 
Step 10 . Turn the actuator upside down and run warm water through the mouthpi[INVESTIGATOR_345234] 30 seconds. See Figure I . 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428802] . If there is any build-up, 
repeat Steps 9 and 10. 
Step 12 . Let the actuator air-dry overnight. See Figure J . 
Figure J 
 
 
Figure J 
Step 13 . When the actuator is dry, put the protective cap on the mouth pi[INVESTIGATOR_345235]. Shake th e inhaler well, remove the cap, 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428803] from your face. (T he counter will count down by 
1 number.) Put the cap back on the mouthpi[INVESTIGATOR_13959]. 
If you need to use your inhaler before the actuator is complete ly dry: 
• Shake as much water off the actuator as you can. 
• Put the cap on the mouthpi[INVESTIGATOR_235712] t hen put the canister in the actuator and make sure 
it fits firmly. 
• Shake the inhaler well and spray it [ADDRESS_428804] fr om your face. 
• Take your VENTOLIN HFA dose as prescribed. 
• Follow cleaning Steps 8 through 13 above 
  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428805] meet the following 7 criteria: 
1. Acceptable start of exhalation with brisk upstroke, no hesitati on or false start, and back 
extrapolation volume (EV) <5% of FVC or 0.150 L, whichever is t he greater. (Refer to 
example in Figure A1-1) 
2. No cough during the first second. 
3. No valsalva maneuver. 
4. No leak. 
5. No obstruction of mouthpi[INVESTIGATOR_13959]. 
6. No extra breaths. 
7. Plateau achieved, ie, the volume-time curve shows no change in volume (<0.025 L) for 
≥[ADDRESS_428806] meets all 7 criteria listed. This is to be c onside red the “gold standard”.  
Useable spi[INVESTIGATOR_280845] 1  and 2 (Figure A1-1). When 
this occurs, repeat testing up to [ADDRESS_428807]’s volume -time spi[INVESTIGATOR_244916], illustrating 
back extrapolation through the ste epest part of the curve, wher e flow is peak expi[INVESTIGATOR_10229] 
(PEF), to determine the new “time zero”. Forced vital capacity (FVC) -4.291 L; back 
extrapolated volume (EV) – 0.123 L (2.9% FVC): back extrapolation line through PEF. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428808] been obtained, apply the fol lowing tests: 
a. The [ADDRESS_428809] FVC obtained at each testing time-point (even if from different 
reproducible tracings), will be collected.  
If acceptability criteria are not met, continue testing until t hey are met or the patient 
cannot/should not continue (maximum of 8 attempts).  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428810] spi[INVESTIGATOR_345236] (provided by [CONTACT_345290]), 
central training provided, qua lification will be required, and specific operating instruction 
will also be provided.  
The following instructions are  supported by [CONTACT_10251]/ERS defined cri teria (Miller 2005). 
FEV [ADDRESS_428811] be capable of accumulating volume for ≥15 s (longer times are 
recommended) and measuring volumes of ≥8 L (body temperature (ie, 37°C), ambient 
pressure, saturated with wa ter vapor, body temperature and pres sure saturated [BTPS]) with 
an accuracy of at least ±3% of reading or ±0.[ADDRESS_428812] be <1.5 cmH 2O L-1 1s -1 
(0.15 kPa L-1 1s -1). The total resistance must be measured with any tubing, valve s, pre filter, 
etc. included that may be inserted between the subject and the spi[INVESTIGATOR_14007]. Some devices may 
exhibit changes in resistan ce due to water vapor condensation, and accuracy requirements 
must be met under BTPS conditi ons for up to eight successive FV C maneuvers performed in 
a [ADDRESS_428813]. Displays of flow vs. 
volume provide more detail for t he initial portion (first 1 s) of the FVC maneuver. Since this 
portion of the maneuver, particularly the peak expi[INVESTIGATOR_216965], is correlated with the 
pleural pressure during the maneuver, the flow –volume display is useful to assess the 
magnitude of effort during the initial portions of the maneuver . The ability to overlay a series 
of flow –volume curves registered at the point of maximal inhalation may  be helpful in 
evaluating repeatability and detecting sub maximal efforts. How ever, if the point of maximal 
inhalation varies between blows, then the interpretation of the se results is difficult because 
the flows at identical measure d volumes are being achieved at d ifferent absolute lung 
volumes. In contrast, display of the FVC maneuver as a volume –time graph provides more 
detail for the latter part of the maneuver. A volume –time tracing of sufficient size also allows 
independent measurement and calculation of parameters from the FVC maneuvers. In a 
display of multiple trials, the sequencing of the blows should be apparent to the user. For the 
start of test display, the volume –time display should include >0.25 s, and preferably 1 s, 
before exhalation starts (zero vo lume). This time period before  there is any change in volume 
is needed to calculate the back extrapolated volume (EV) and to  evaluate effort during the 
initial portion of the maneuver. Time zero, as defined by [CONTACT_345291], m ust be presented as the zero 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428814]. 
When a volume –time curve is plotted as hardcopy, the volume scale must be ≥10 mm L-1 
(BTPS). For a screen display, 5 mm L-1 is satisfactory (Table A1-1). 
Table A1-1.  Recommended Minimal Scale Factors for Time, Volume  and 
Flow on Graphical Output 
Parameter Instrument Display Hardcopy Graphical 
Output 
 Resolution Required Scale Factor Resolution Required 
Volume* 0.050 L 5 mm-L-1 0.050 L 
Flow* 0.200 L-s-1 2.5 mm L-1 s-1 0.200 L-s-1 
Time 0.2 s 10 mm-s-1 0.2 s 
*The correct aspect ratio for flow versus volume display is two  units of flow per one unit of volume 
 
The time scale should be ≥20 mm -s -1, and larger time scales are preferred ( ≥30 mm -s -1) 
when manual measurements are made. When the volume –time plot is used in conjunction 
with a flow –volume curve (ie, both display methods are provided for interpr etations and no 
hand measurements are performed ), the time scale requirement is  reduced to 10 mm-s -1 from 
the usually required minimum of 20 mm-s -1 (Table A1-1). The rationale for this exception is 
that the flow –volume curve can provide the means for quality assessment durin g the initial 
portion of the FVC maneuver. The volume –time curve can be used to evaluate the latter part 
of the FVC maneuver, making the time scale less critical. 
Validation 
It is strongly recommended that spi[INVESTIGATOR_345237] a computer 
driven mechanical syringe or its equivalent, in order to test t he range of exhalations that are 
likely to be encountered in the  test population. Testing the pe rformance of equipment is not 
part of the usual laboratory procedures. 
Quality Control 
Attention to equipment quality cont rol and calibration is an im portant part of Good 
Laboratory Practice. At a minimum, the requirements are as foll ows: 1) a log of calibration 
results is maintained; 2) the documentation of repairs or other  alterations which return the 
equipment to acceptable opera tion; 3) the dates of computer sof tware and hardware updates 
or changes; and 4) if equipment is changed or relocated (eg, in dustrial surveys), calibration 
checks and quality control proce dures must be repeated before f urther testing begins. 
Key aspects of equipment quality control are summarized in Tabl e A1-2. 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428815] Minimal Interval Action 
Volume Daily Calibration check with a 3 L syringe 
Leak Daily 2 cmH 2O (0.3 kPa) constant pressure for [ADDRESS_428816] using “known” subject  
 
Calibration is the procedure fo r establishing the relationship between sensor determined 
values of flow or volume and the  actual flow or volume. A calib ration check is different from 
calibration and is the procedure used to validate that the devi ce is within calibration limits, 
eg, ±3% of true. If a device fail s its calibration check, then new calibration procedure or 
equipment maintenance is requi red. Calibration checks must be u ndertaken daily, or more 
frequently, if specified by [CONTACT_3455]. The syringe used to check the volume 
calibration of spi[INVESTIGATOR_345238] ±15 mL or ± 0.5% of the full scale (15 
mL for a 3 L syringe), and the manufacturer must provide recomm endations concerning 
appropriate intervals between syringe calibration checks. Users  should be aware that a 
syringe with an adjustable or variable stop may be out of calib ration if the stop is reset or 
accidentally moved. Calibration syringes should be periodically  (eg, monthly) leak tested at 
more than one volume up to their m aximum; this can be done by a ttempting to empty them 
with the outlet corked. A dr opped or damaged syringe should be considered out of calibration 
until it is checked. 
With regard to time, assessing mechanical recorder time scale a ccuracy with a stopwatch 
must be performed at least qua rterly. An accuracy of within 2% must be achieved. 
Quality Control for Vol ume Measuring Devices 
The volume accuracy of the spi[INVESTIGATOR_345239], with a single 
discharge of a 3 L calibrated syringe. Daily calibration checki ng is highly recommended so 
that the onset of a problem can be determined within 1 day and also to help define day to day 
laboratory variability. More fre quent checks may be required in  special circumstances, such 
as: 1) during industrial surveys or other studies in which a la rge number of subject 
maneuvers are carried out, the equipment’s cal ibration should be checked more frequently 
than daily; and 2) when the ambient  temperature is changing (eg , field studies), volume 
accuracy must be checked more frequently than daily and the BTP S correction factor 
appropriately updated.  
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428817] be considered in determ ining whether the measured 
volume is within acceptable limit s. For example, if the syringe  has an accuracy of 0.5%, a 
reading of ±3.5% is appropriate. 
The calibration syringe should be stored and used in such a way  as to maintain the same 
temperature and humidity of the testing site. This is best acco mplished by [CONTACT_9377][INVESTIGATOR_345240], but out of direct  sunlight and away from heat 
sources. 
Volume type spi[INVESTIGATOR_345241] y day. The importance of 
undertaking this daily test cannot be overstressed. Leaks can b e detected by [CONTACT_2931] a 
constant positive pressure of ≥3.0 cmH 2O (0.3 kPa) with the spi[INVESTIGATOR_345242] 
(preferably at or including the mouthpi[INVESTIGATOR_13959]). Any observed volum e loss of 0.[ADDRESS_428818]. The measured 
volume should be within ±3.5% of the reading or 65 mL, whicheve r is greater. This limit 
includes the 0.5% accuracy limit for a 3-L syringe. The lineari ty check procedure provided 
by [CONTACT_345292] t he following procedures: 
1) consecutive injections of 1-L volume increments while compar ing observed volume with 
the corresponding cumulative measured volume (eg, 0 –1,1–2, 2–3,…6– 7 and 7 –8 L, for an 8-
L spi[INVESTIGATOR_14007]); and 2) injection of a 3-L volume starting at a m inimal spi[INVESTIGATOR_345243], then 
repeating this with a 1-L increment in the start position (eg, 0–3, 1–4, 2–5, 3–6, 4–7, and 5 –
8 L, for an 8-L spi[INVESTIGATOR_14007]). The linearity check is considered acceptable if the spi[INVESTIGATOR_345244]. 
Quality Control for Flow Measuring Devices 
With regards to volume accuracy, calibration checks must be und ertaken at least daily, using 
a 3-L syringe discharged at least three times to give a range o f flows varying between 0.5 and 
12 L-s -1 (with 3-L injection times of 6 s and 0.5 s). The volume at eac h flow should meet the 
accuracy requirement of ±3.5%. For  devices using disposable flo w sensors, a new sensor 
from the supply used for subject tests should be tested each da y. 
For linearity, a volume calibr ation check should be performed w eekly with a 3-L syringe to 
deliver three relativel y constant flows at a low flow, then thr ee at a mid-range flow and 
finally three at a high flow. The volumes achieved at each of t hese flows should each meet 
the accuracy requirement of ±3.5%. 
VITAL CAPACITY AND INSPI[INVESTIGATOR_345245] (VC) and inspi[INVESTIGATOR_62835] y, the spi[INVESTIGATOR_345246] (as described p reviously) and be capable 
of accumulating volume for >30 s. E xpi[INVESTIGATOR_345247], idea lly, both inspi[INVESTIGATOR_345248], Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428819] has obtained a pla teau in the expi[INVESTIGATOR_21266]. 
For display of the slow VC, the time scale may be reduced to 5 mm-s -1. 
TECHNICAL CONSIDERATIONS 
Minimal Recommendations for Spi[INVESTIGATOR_345249]. Spi[INVESTIGATOR_345250]. In some circum stances, it may be 
appropriate to exceed these requi rements (ie, in some research/ surveillance applications). 
Instrumentation recommendations  should be followed to provide a ccurate spi[INVESTIGATOR_345251] y and from one time period to 
another. The accuracy of a spi[INVESTIGATOR_345252], 
from the volume or flow transducer and the use of an in line fi lter, to the recorder, display or 
processor. Changes in any aspect of the equipment or errors at any step in the process can 
affect the accuracy of the results. For example, if the BTPS co rrection factor is wrong, an 
accurately measured FVC will be i ncorrectly reported. Spi[INVESTIGATOR_345253] A1-3, but must meet the rec ommendations for those that 
are measured. Accuracy and repeatability recommendations apply over the entire volume 
range of the instrument. 
Table A1-[ADDRESS_428820] Range/Accuracy 
(BTPS) Flow 
Range 
(L-s-1) Resistance and 
Back Pressure Test Signal 
VC 0.5–8 L, ±3% of reading or 
±0.050 L, whichever is greater 0-14  3-L Calibration syringe 
FVC 0.5–8 L, ±3% of reading or 
±0.050 L, whichever is greater 0-14 <1.5 cmH 2O L-1 s-1 
(0.15 kPa L-1s-1) 24 ATS waveforms, 3-L 
Cal Syringe 
FEV 1 0.5–8 L, ±3% of reading or 
±0.050 L, whichever is greater 0-14 <1.5 cmH 2O L-1 s-1 
(0.15 kPa L-1s-1) 24 ATS waveforms 
Time 
Zero The time point from which all 
FEVt measurements are taken  Back extrapolation  
FEVt: forced expi[INVESTIGATOR_3741] t seconds 
 
BTPS correction  
All spi[INVESTIGATOR_345254] (measuring temperature 
and barometric pressure) proven eff ective by [CONTACT_3455]. For volume-type spi[INVESTIGATOR_75029], 
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-[ADDRESS_428821] always be 
recorded with an accuracy of ±1°C. In situations where the ambi ent air temperature is 
changing rapi[INVESTIGATOR_375] (>3°C in <30 min), continuous temperature corr ections may be necessary. 
Spi[INVESTIGATOR_345255]: 17°C is the  lower limit for ambient tempe rature, unless a manufacturer 
states that their spi[INVESTIGATOR_345256] a mbient temperatures. If 
barometric pressure is not used i n calculating the BTPS correct ion factor, the range of 
barometric pressures over which the BTPS correction factor is v alid must be published. 
   
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol Pearl Therapeutics, Inc. 
Clinical Study Protocol: PT010018-00 Version 1.0 
Confidential and Proprietary Page 96 of 96Appendix 7 Investigator’s Signature
[CONTACT_2759]: A Study to Assess the Pharmacokinetics and Safety of PT010 in 
Subjects With Moderate to Severe COPD Following Single and Repeat Dose Administration
Study Number: PT010018
Final Date:
I have read the protocol described above. I agree to comply wit h all applicable regulations 
and to conduct the study as described in the protocol. I agree:
•To assume responsibility for the proper conduct of the study at  this site. 
•To conduct the study in compliance with the protocol and with a ny other study conduct procedures 
provided by [CONTACT_99305], Inc. (hereafter referred to as Pearl). 
•Not to implement any changes to the protocol without agreement from the Sponsor and prior review 
and written approval from the IRB/IEC, except where necessary t o eliminate an immediate hazard to 
the subjects, or for administrative aspects of the study (where  permitted by [CONTACT_124519]). 
•That I am aware of, and will fully comply with GCP and all appl icable regulatory requirements.  
•That I am thoroughly familiar with the appropriate use of the i nvestigational product(s), and other 
information provided by [CONTACT_345293], but not limited to, th e following: the protocol and the 
current Investigator’s Brochure (IB).
•To ensure that all persons assisting me with the study are qual ified, adequately informed about the 
investigational product(s) and of their study related duties an d functions. 
•To supply Pearl with any necessary information regarding owners hip interest and financial ties; to 
promptly update this information if any relevant changes occur during the course of the study and for 
1 year following completion of the study; and agree that Pearl may disclose any information it has 
about such ownership interests and financial ties to regulatory  authorities. 
•I agree to report all informatio n or data in accordance with th e protocol and any other study conduct 
procedures provided by [CONTACT_345290].  
•That since the information in this protocol and IB is confident ial, I understand that its disclosure to 
any third parties, other than those involved in approval, super vision or conduct of the study is 
prohibited. 
•To accurately transfer all required data from each subject’s source document to the CRFs. The CRFs 
will be provided to the Sponsor in a timely manner at the compl etion of the study, or as otherwise 
specified by [CONTACT_1034]. 
•To allow authorized representativ es of Pearl or regulatory auth ority representatives to conduct on site 
visits to review, audit and copy study documents. I will person ally meet with these representatives to 
answer any study related questions. 
S i g n e d :              D a t e :        
N a m e :              
S i t e  N a m e :             